MannKind Corporation
(NASDAQ:MNKD)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It...

Website: http://www.mannkindcorp.com

Founded: 1991

Full Time Employees: 232

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2011-02-14	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2010-02-14	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2009-02-14	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2008-02-14	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2007-02-14	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2006-02-14	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2005-02-14	2004-12-31	2004-09-30	2004-06-30	2004-02-14

revenues:
commercial product sales	33,907,000	50,405,000	22,305,000	22,454,000	18,973,000
collaborations and services	23,515,000	27,986,000	26,506,000	22,845,000	29,376,000
royalties	32,749,000	33,564,000	33,319,000	31,228,000	30,005,000											304,000
total revenues	90,171,000	111,955,000	82,130,000	76,527,000	78,354,000	76,776,000	70,079,000	72,386,000	66,263,000	58,472,000	51,253,000	48,611,000	40,626,000	36,059,000	32,825,000	18,894,000	11,992,000	12,515,000	22,211,000	23,280,000	17,436,000	18,443,000	15,352,000	15,114,000	16,235,000	15,993,000	14,595,000	15,002,000	17,448,000	16,032,000	4,469,000	3,893,000	3,465,000	4,530,000	2,043,000	2,163,000	3,009,000
yoy	15.08%	45.82%	17.20%	5.72%	18.25%	31.30%	36.73%	48.91%	63.10%	62.16%	56.14%	157.28%	238.78%	188.13%	47.79%	-18.84%	-31.22%	-32.14%	44.68%	54.03%	7.40%	15.32%	5.19%	0.75%	-6.95%	-0.24%	226.58%	285.36%	403.55%	253.91%	118.75%	79.98%	15.15%
qoq	-19.46%	36.31%	7.32%	-2.33%	2.06%	9.56%	-3.19%	9.24%	13.32%	14.09%	5.43%	19.65%	12.67%	9.85%	73.73%	57.56%	-4.18%	-43.65%	-4.59%	33.52%	-5.46%	20.13%	1.57%	-6.90%	1.51%	9.58%	-2.71%	-14.02%	8.83%	258.74%	14.80%	12.35%	-23.51%	121.73%	-5.55%	-28.12%
expenses:
cost of goods sold – commercial, excluding amortization of acquired intangible assets	7,509,000
cost of revenue – collaborations and services	9,964,000	15,746,000	15,705,000	15,961,000	13,748,000	14,796,000	14,826,000	14,772,000	14,779,000	11,953,000	10,259,000	9,013,000	10,683,000
research and development	17,231,000	27,588,000	14,063,000	13,675,000	11,022,000	11,138,000	12,926,000	11,816,000	10,013,000	9,236,000	9,989,000	6,453,000	5,605,000	7,156,000	4,136,000	4,893,000	3,536,000	3,886,000	3,655,000	2,329,000	2,442,000	1,545,000	1,484,000	1,464,000	1,755,000	2,021,000	1,580,000	1,632,000	1,667,000	1,084,000	2,043,000	2,967,000	2,644,000	3,507,000	4,361,000	3,123,000	3,129,000	1,560,000	3,917,000	4,310,000	5,130,000	6,219,000	6,341,000	7,737,000	9,377,000	17,560,000	19,178,000	37,323,000	26,182,000	28,988,000	27,281,000	27,052,000	26,398,000	25,275,000	25,453,000	26,638,000	24,156,000	20,242,000	23,132,000	30,296,000	26,289,000	1,292,381,000	24,217,000	31,411,000	26,160,000	30,491,000		43,099,000	30,494,000	39,849,000	42,889,000		68,777,000	55,645,000	67,574,000	58,445,000		66,751,000	64,825,000	61,480,000	63,788,000		59,740,000	50,785,000	45,321,000	35,950,000		28,589,000	24,466,000	23,596,000	18,696,000		20,461,000	11,695,000
selling, general and administrative	54,085,000	58,411,000	29,088,000	31,622,000	25,014,000									17,344,500	22,638,000	26,043,000	20,697,000	22,727,000	17,221,000	20,056,000	17,413,000	17,121,000	13,899,000	13,670,000	14,350,000	15,721,000	16,666,000	16,609,000	25,673,000	17,976,000	19,394,000	21,731,000	20,618,000	23,278,000	17,725,000	18,566,000	15,389,000	15,333,000	13,135,000	11,110,000
amortization of acquired intangible assets	4,367,000
loss on foreign currency transaction	-1,318,000	-3,000	-120,000	5,363,000	2,509,000	-4,433,000	2,454,000	-529,000	-1,399,000			251,000	954,000
total expenses	91,838,000	119,642,000	63,234,000	71,228,000	56,061,000	50,281,000	57,319,000	55,776,000	49,541,000	50,614,000	46,156,000	46,890,000	46,624,000	48,849,000	42,435,000	39,348,000	33,248,000	36,483,000	28,801,000	33,553,000	23,627,000	42,190,000	24,482,000	23,029,000	23,356,000	27,345,000	23,374,000	25,954,000	30,962,000	23,762,000	26,012,000	24,430,000	30,254,000	33,367,000	30,222,000	33,734,000	22,611,000	24,237,000	44,125,000
income from operations	-1,667,000	-7,687,000	18,896,000	5,299,000	22,293,000	26,495,000	12,760,000	16,610,000	16,722,000	7,858,000	5,097,000	1,721,000	-5,998,000	-12,790,000	-9,610,000	-20,454,000	-21,256,000	-23,968,000	-6,590,000	-10,273,000	-6,191,000	-23,747,000	-9,130,000	-7,915,000	-7,121,000	-11,352,000	-8,779,000	-10,952,000	-13,514,000	-7,730,000	-21,543,000	-20,537,000	-26,789,000	-28,837,000	-28,179,000	-31,571,000	-19,602,000	-11,833,000	118,229,000	-19,124,000	-20,013,000	-272,863,000	-26,003,000	-24,051,000	-21,738,000	-30,103,000	-38,266,000	-69,846,000	-41,411,000	-46,617,000	-44,762,000	-41,585,000	-36,437,000	-33,486,000	-35,487,000	-44,054,000	-33,933,000	-30,579,000	-32,773,000	-39,186,000	-38,001,000	-1,811,767,000	-32,093,000	-42,540,000	-37,263,000	-40,601,000		-55,819,000	-42,767,000	-53,386,000	-57,806,000		-81,755,000	-69,080,000	-80,864,000	-74,065,000		-79,067,000	-75,569,000	-75,393,000	-77,328,000		-71,798,000	-61,134,000	-55,777,000	-44,988,000		-35,046,000	-32,862,000	-27,567,000	-22,647,000		-21,696,000	-20,503,000	-18,382,000
yoy	-107.48%	-129.01%	48.09%	-68.10%	33.32%	237.17%	150.34%	865.14%	-378.79%	-161.44%	-153.04%	-108.41%	-71.78%	-46.64%	45.83%	99.10%	243.34%	0.93%	-27.82%	29.79%	-13.06%	109.19%	4.00%	-27.73%	-47.31%	46.86%	-59.25%	-46.67%	-49.55%	-73.19%	-23.55%	-34.95%	36.66%	143.70%	-123.83%	65.09%	-2.05%	-95.66%	-554.67%	-20.49%	-7.94%	806.43%	-32.05%	-65.57%	-47.51%	-35.42%	-14.51%	67.96%	13.65%	39.21%	26.14%	-5.60%	7.38%	9.51%	8.28%	12.42%	-10.70%	-98.31%	2.12%	-7.88%	1.98%	4362.37%		-23.79%	-12.87%	-23.95%			-47.69%	-22.72%	-28.51%			-12.63%	7.01%	-1.76%			5.25%	23.32%	38.64%			74.44%	69.73%	63.20%			51.47%	34.45%	23.20%
qoq	-78.31%	-140.68%	256.60%	-76.23%	-15.86%	107.64%	-23.18%	-0.67%	112.80%	54.17%	196.17%	-128.69%	-53.10%	33.09%	-53.02%	-3.77%	-11.32%	263.70%	-35.85%	65.93%	-73.93%	160.10%	15.35%	11.15%	-37.27%	29.31%	-19.84%	-18.96%	74.83%	-64.12%	4.90%	-23.34%	-7.10%	2.34%	-10.74%	61.06%	65.66%	-110.01%	-718.22%	-4.44%	-92.67%	949.35%	8.12%	10.64%	-27.79%	-21.33%	-45.21%	68.67%	-11.17%	4.14%	7.64%	14.13%	8.81%	-5.64%	-19.45%	29.83%	10.97%	-6.69%	-16.37%	3.12%	-97.90%	5545.37%	-24.56%	14.16%	-8.22%			30.52%	-19.89%	-7.65%			18.35%	-14.57%	9.18%			4.63%	0.23%	-2.50%			17.44%	9.60%	23.98%			6.65%	19.21%	21.72%			5.82%	11.54%
operating margin %	-1.85%	-6.87%	23.01%	6.92%	28.45%	34.51%	18.21%	22.95%	25.24%	13.44%	9.94%	3.54%	-14.76%	-35.47%	-29.28%	-108.26%	-177.25%	-191.51%	-29.67%	-44.13%	-35.51%	-128.76%	-59.47%	-52.37%	-43.86%	-70.98%	-60.15%	-73.00%	-77.45%	-48.22%	-482.05%	-527.54%	-773.13%	-636.58%	-1379.30%	-1459.59%	-651.45%	-Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%
other income:
interest income	1,429,000	1,637,000	2,628,000	1,832,000	1,956,000	2,825,000	3,179,000	3,177,000	3,434,000	1,725,000	1,580,000	1,547,000	1,302,000	957,000	663,000	516,000	377,000	48,000	36,000	25,000	3,000	2,000	18,000	14,000	133,000	203,000	220,000	255,000	318,000	196,000	144,000	55,000	106,000	115,000	65,000	58,000	55,000	15,000	28,000	26,000	15,000	10,000	2,000	3,000	3,000	5,000	1,000	1,000	1,000	4,000	2,000	1,000	1,000	5,000		1,000	1,000			2,000	15,000	36,986,000	18,000	16,000	3,000	3,000		3,000	9,000	27,000	31,000		271,000	715,000	1,222,000	2,921,000		4,996,000	3,238,000	4,261,000	5,280,000		1,526,000	802,000	971,000	1,380,000		1,669,000	1,161,000	405,000	472,000		436,000	275,000	123,000
interest expense	-7,478,000	-7,536,000	-1,364,000	-285,000	-4,645,000	-1,562,000	-1,801,000	-6,051,000	-2,567,000	-2,677,000	-2,815,000	-6,873,000
interest expense on liability for sale of future royalties	-2,563,000	-3,885,000	-3,514,000	-3,473,000	-3,577,000	-3,452,000	-4,089,000	-4,383,000	-4,248,000
interest expense on financing liability	-2,393,000	-2,451,000	-2,456,000	-2,433,000	-2,410,000	-2,467,000	-2,470,000	-2,444,000	-2,447,000	-2,493,000	-2,459,000	-2,449,000	-2,424,000	-2,478,000	-2,466,000	-2,443,000	-2,371,000
loss on settlement of debt	-917,000
other expense	-2,777,000											-143,000									-276,000				-4,000
total other expense	-14,699,000			-4,359,000	-8,676,000	-18,050,000	110,000	-18,301,000	-5,828,000	-4,896,000	-3,376,000	-6,986,000	-3,797,000	-5,157,000	-4,822,000	-8,569,000	-4,742,000			-25,250,000	-6,725,000	-2,664,000	-2,343,000	-2,337,000	-2,201,000	-2,911,000	-1,591,000	-1,435,000	-1,369,000	-2,029,750	-2,625,000					-3,768,000
income before income tax expense	-16,366,000	-20,931,000	7,781,000	940,000	13,617,000	8,445,000	12,870,000	-1,691,000	10,894,000	-3,334,750	1,721,000
income tax expense	253,000	-4,983,000	-204,000	272,000	459,000	1,023,000	1,320,000	323,000	264,000																					-60,000		-240,000
net income	-16,619,000	-15,948,000	7,985,000	668,000	13,158,000	7,422,000	11,550,000	-2,014,000	10,630,000	1,401,000	1,721,000	-5,265,000	-9,795,000	-17,947,000	-14,432,000	-29,023,000	-25,998,000	-28,061,000	-4,426,000	-35,523,000	-12,916,000	-26,411,000	-11,255,000	-10,252,000	-9,322,000	-14,263,000	-10,370,000	-12,387,000	-14,883,000	-9,751,000	-24,168,000	-22,675,000	-30,385,000	-32,784,000	-32,886,000	-35,339,000	-16,324,000	53,974,000	126,520,000	-29,959,000	-24,873,000	-277,019,000	-31,857,000	-28,910,000	-30,658,000	-36,441,000	-36,520,000	-73,365,000	-52,056,000	-53,583,000	-50,818,000	-46,124,000	-40,965,000	-51,781,000	-42,834,000	-36,578,000	-38,173,000	-36,397,000	-38,402,000	-44,480,000	-41,525,000	-1,816,267,000	-38,306,000	-45,303,000	-42,251,000	-44,700,000		-59,533,000	-45,555,000	-55,604,000	-59,412,000		-83,295,000	-68,496,000	-79,826,000	-71,421,000		-75,013,000	-73,047,000	-71,989,000	-73,141,000		-71,268,000	-60,970,000	-54,751,000	-43,559,000		-33,291,000	-31,730,000	-27,155,000	-22,162,000		-21,150,000	-20,188,000	-18,245,000
yoy	-226.30%	-314.87%	-30.87%	-133.17%	23.78%	429.76%	571.12%	-61.75%	-208.52%	-107.81%	-111.92%	-81.86%	-62.32%	-36.04%	226.07%	-18.30%	101.29%	6.25%	-60.68%	246.50%	38.55%	85.17%	8.53%	-17.24%	-37.36%	46.27%	-57.09%	-45.37%	-51.02%	-70.26%	-26.51%	-35.84%	86.14%	-160.74%	-125.99%	17.96%	-34.37%	-119.48%	-497.15%	3.63%	-18.87%	660.18%	-12.77%	-60.59%	-41.11%	-31.99%	-28.14%	59.06%	27.07%	3.48%	18.64%	26.10%	7.31%	42.27%	11.54%	-17.77%	-8.07%	-98.00%	0.25%	-1.82%	-1.72%	3963.24%		-23.90%	-7.25%	-19.61%			-45.31%	-18.82%	-25.57%			-8.69%	9.28%	-0.79%			2.50%	18.07%	33.59%			83.14%	72.55%	60.41%			50.02%	34.51%	21.47%
qoq	4.21%	-299.72%	1095.36%	-94.92%	77.28%	-35.74%	-673.49%	-118.95%	658.74%	-18.59%	-132.69%	-46.25%	-45.42%	24.36%	-50.27%	11.64%	-7.35%	534.00%	-87.54%	175.03%	-51.10%	134.66%	9.78%	9.98%	-34.64%	37.54%	-16.28%	-16.77%	52.63%	-59.65%	6.58%	-25.37%	-7.32%	-0.31%	-6.94%	116.48%	-130.24%	-57.34%	-522.31%	20.45%	-91.02%	769.57%	10.19%	-5.70%	-15.87%	-0.22%	-50.22%	40.93%	-2.85%	5.44%	10.18%	12.59%	-20.89%	20.89%	17.10%	-4.18%	4.88%	-5.22%	-13.66%	7.12%	-97.71%	4641.47%	-15.44%	7.22%	-5.48%			30.68%	-18.07%	-6.41%			21.61%	-14.19%	11.77%			2.69%	1.47%	-1.58%			16.89%	11.36%	25.69%			4.92%	16.85%	22.53%			4.77%	10.65%
net income margin %	-18.43%	-14.25%	9.72%	0.87%	16.79%	9.67%	16.48%	-2.78%	16.04%	2.40%	3.36%	-10.83%	-24.11%	-49.77%	-43.97%	-153.61%	-216.79%	-224.22%	-19.93%	-152.59%	-74.08%	-143.20%	-73.31%	-67.83%	-57.42%	-89.18%	-71.05%	-82.57%	-85.30%	-60.82%	-540.79%	-582.46%	-876.91%	-723.71%	-1609.69%	-1633.80%	-542.51%	Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%
net income per share	-0.05	-0.05	0.03		0.04	0.03	0.04	-0.01	0.04	0.01	0.01	-0.02	-0.04	-0.07	-0.06	-0.11	-0.1	-0.11	-0.02	-0.14	-0.05	-0.12	-0.05	-0.05	-0.04	-0.07	-0.05	-0.07	-0.08	-0.04	-0.16	-0.16	-0.25	-0.29	-0.31	-0.35	-0.17	1.21	0.26	-0.07	-0.06	-0.68	-0.08	-0.07	-0.08	-0.09	-0.09	-0.19	-0.14	-0.16	-0.17	-0.16	-0.15	-0.23	-0.22	-0.23	-0.27	-0.3	-0.31	-0.37	-0.34		-0.33	-0.4	-0.37	-0.4		-0.53	-0.42	-0.54	-0.58		-0.81	-0.67	-0.79	-0.7		-0.69	-0.99	-0.98	-1		-1.32	-1.23	-1.1	-0.87		-0.64	-0.73	-0.83
weighted-average shares used for eps calculation	308,267	305,639	306,806	304,954	303,481	274,415	274,998	273,056	270,356	267,014	268,732	265,626
cost of goods sold – commercial		3,218,250	4,498,000	4,607,000	3,768,000
impairment of available-for-sale investment			-6,409,000
other income							32,000			-164,000	318,000		111,000	105,000	-207,000			1,000	1,000	35,000		6,000	14,000	14,000		-21,000	-52,000	-17,000	-14,000	-508,000	10,000	30,000	31,000				14,000	16,000	-27,000	-5,959,000	67,000	-104,000	67,000	-10,000	1,413,000	41,000	7,898,000	-370,000	-5,890,000	-683,000	10,000	15,000	23,000	-13,269,000	-2,651,000	13,347,000	1,382,000	65,000	79,000	47,000	1,350,000	-1,267,000	-627,000	1,948,000	-1,257,000	-790,000		-452,000	149,000	283,000	71,000		-55,000	-7,000	-60,000	60,000		-355,000	62,000	44,000	52,000		48,000	51,000	59,000	50,000		86,000	-29,000	7,000	14,000		111,000	40,000	14,000
gain on bargain purchase							5,259,000
total other income		-6,037,500	-11,115,000															-7,452,750	2,164,000														-3,596,000	-3,896,000	-4,707,000		3,278,000
loss on available-for-sale securities
net revenue – commercial product sales						14,818,000	19,728,000	20,780,000	18,764,000	20,195,000	17,927,000	18,345,000	17,562,000
revenue – collaborations and services						18,532,500	23,268,000	26,014,000	24,848,000	17,249,000	13,108,000	11,211,000	11,386,000
royalties – collaboration						18,831,500	27,083,000	25,592,000
cost of goods sold						4,808,000	3,197,000	5,605,000	3,819,000	6,114,000	3,995,000	5,224,000	5,530,000	4,081,000	5,021,000	4,617,000	2,284,000	4,295,000	3,812,000	4,411,000	4,315,000	3,652,000	3,591,000	3,677,000	4,164,000	4,632,000	7,099,000	4,327,000	4,020,000	4,996,000	5,303,000	5,095,000	4,008,000	5,018,000	4,575,000	5,086,000	2,548,000	1,554,000	4,331,000
selling						9,047,250	13,093,000	11,495,000	11,601,000	11,024,000	13,440,000	14,002,000	13,310,000
general and administrative						8,542,000	10,823,000	12,617,000	10,728,000	9,511,000	10,538,000	11,947,000	10,542,000																												7,351,000	8,311,000	11,547,000	10,623,000	10,479,000	12,543,000	19,088,000	32,523,000	15,229,000	17,629,000	17,481,000	14,533,000	10,039,000	8,211,000	10,069,000	17,416,000	9,777,000	10,337,000	9,641,000	8,890,000	11,762,000	351,363,000	7,876,000	11,129,000	11,196,000	10,110,000		12,720,000	12,273,000	13,537,000	14,917,000		12,978,000	13,435,000	13,290,000	15,640,000		12,316,000	10,744,000	13,913,000	13,550,000		12,058,000	10,349,000	10,456,000	9,138,000		6,457,000	8,396,000	3,971,000	3,951,000		1,235,000	8,808,000
loss on extinguishment of debt						-1,762,500		-7,050,000												-22,130,000										-191,250	-712,000		-825,000	-207,500		-830,000							-1,049,000
gain on available-for-sale securities						-387,500		-1,550,000		233,000		932,000
royalties – collaborations									22,651,000	21,028,000	20,218,000	19,055,000	11,678,000
gain on foreign currency transaction										-215,000	-2,065,000
benefit from income taxes
loss before income tax expense												-5,265,000	-9,795,000
interest expense on notes													-2,786,000	-2,809,000	-2,812,000	-6,642,000	-2,748,000	-4,261,000	-2,709,000	-2,812,000	-5,422,000	-1,104,000	-1,057,000	-1,084,000	-1,071,000	-1,021,000	-4,126,000	-564,000	-593,000	-620,000	-993,000	-1,709,000	-1,794,000	-2,056,000	-2,310,000	-2,422,000	-2,706,000	-3,009,000	-4,166,000	-4,181,000	-4,221,000	-3,332,000	-4,145,000	-4,131,000	-9,622,000	-5,654,000	-5,424,000	-2,429,000	-4,042,000
shares used to compute net loss per share – basic and diluted													263,969
net revenue — commercial product sales														17,440,000	16,259,000	12,722,000	9,826,000	11,340,000	9,753,000	9,976,000	8,099,000	10,064,000	7,275,000	6,985,000	8,000,000
revenue — collaborations and services														9,544,000	10,346,000	5,868,000	2,166,000	1,175,000	12,458,000	13,304,000	9,337,000	8,379,000	8,077,000	8,129,000	8,235,000
royalties — collaborations														9,075,000	6,220,000
cost of revenue — collaborations and services														12,043,000	12,439,000	8,298,000	8,714,000	7,139,000	6,075,000	5,515,000	3,295,000	2,631,000	1,581,000	1,983,000	3,362,000
asset impairment																		26,500	106,000			472,250		368,000
gain on foreign currency translation														-2,071,250	-1,799,000		-1,983,000				-3,838,000				-1,796,000	2,582,000	-3,807,000
loss on purchase commitments																				339,000
gain on extinguishment of debt																		-4,300,000	4,930,000								3,529,000					772,000
income before provision for income taxes														-17,363,250	-14,432,000	-29,023,000	-25,998,000	-13,216,250	-4,426,000	-35,523,000	-12,916,000	-7,761,750	-11,473,000	-10,252,000	-9,322,000	-9,410,000	-10,370,000	-12,387,000	-14,883,000	-19,246,000	-24,168,000	-22,435,000	-30,385,000																					-29,498,250	-43,242,000	-36,578,000	-38,173,000	-36,397,000	-38,402,000	-44,480,000	-41,525,000		-38,306,000	-45,303,000	-42,251,000	-44,700,000		-59,533,000	-45,555,000	-55,604,000	-59,412,000		-83,293,000	-68,496,000	-79,826,000	-71,421,000		-75,010,000	-73,047,000	-71,989,000	-73,141,000		-71,268,000	-60,970,000	-54,747,000	-43,558,000		-33,291,000	-31,730,000	-27,155,000	-22,161,000		-21,149,000	-20,188,000	-18,245,000
provision for income taxes
shares used to compute net loss per share - basic and diluted														63,743.5	259,300	253,644	251,887	62,156	249,910
loss on foreign currency translation																-4,503,000		-1,564,000	-2,068,000	903,000		4,008,000	3,927,000	1,867,000				1,247,000	-1,935,000	-1,361,000	-728,000	-5,363,000	2,984,000	1,564,000	3,684,000	6,848,000	1,545,000
interest expense on mann group promissory notes																		-373,000	-94,000	-368,000	-1,030,000
shares used to compute basic and diluted net loss per share																				249,295	246,631	54,639.75	229,668	213,880	212,467	47,946.5	199,906	188,054	187,434	34,576.75	153,597	140,054	120,911			99,864	95,744			455,305	428,858	4,431	405,199	401,018	398,916
interest expense on promissory notes																						-1,297,000	-1,318,000	-1,281,000	-1,259,000	-1,251,000	-1,162,000
benefit for income taxes																						54,500	218,000
impairment of commitment asset																									1,521,000
net revenue - commercial product sales																										4,385,750	6,402,000	6,065,000	5,076,000	5,734,000	4,387,000	3,753,000	3,402,000	4,466,000	1,981,000		1,196,000	143,250	573,000
revenue - collaborations and services																										7,375,500	8,193,000	8,937,000	12,372,000
revenue - other																														13,250		53,000		1,000
cost of revenue - collaborations and services																										1,378,000	1,836,000	2,139,000	1,537,000
interest expense on note payable to related party																												-1,109,000	-1,080,000	-1,089,000	-1,074,000	-1,046,000	-1,114,000																	-1,280,750	-1,745,000	-1,689,000	-1,689,000	-2,170,000	-2,245,000	-3,028,000	-3,048,000	-3,034,000	-2,863,000	-2,509,000	-2,476,000	-19,927,000	-2,773,000	-2,851,000	-2,523,000	-2,102,000		-951,500	-1,816,000	-1,398,000	-593,000
net revenue - collaborations																														58,000	82,000
property and equipment impairment																																			92,000	111,000
gain on purchase commitments
change in fair value of warrant liability																																			-1,289,000	147,000	6,629,000	-2,510,000	13,185,000
net revenue - collaboration																																87,000	63,000	63,000	62,000		63,000	40,445,250	161,781,000
total other																																-1,898,000
product costs - collaboration																																						5,685,500	22,742,000
gain on purchase commitment																																		-53,750	-215,000
interest expense on note payable to principal stockholder																																		-1,174,000	-1,173,000	-721,000	-714,000			-721,000	-721,000	-730,000	-729,000	-721,000	-714,000	-730,000	-729,000	-721,000	-714,000																																		-822,000	-689,000
income before benefit for income taxes																																		-21,137,250	-32,886,000
income tax benefit																																																							-408,000
shares used to compute basic net income per share																																		4,109	104,703			-362,135	478,137
shares used to compute diluted net income per share																																		4,109	104,703			-362,281	482,744
net revenue—commercial product sales																																				1,548,000
net revenue—collaboration																																				63,000
revenue—other																																				552,000
loss before benefit for income taxes																																				-35,339,000	-16,324,000				-24,873,000	-277,019,000	-31,857,000	-28,910,000	-30,658,000	-36,441,000	-36,520,000	-73,365,000	-52,056,000	-53,583,000	-50,818,000	-46,124,000	-40,965,000
revenue - bulk insulin sales																																					1,750,000
revenue:
total net revenue																																						12,404,000	162,354,000
expense:
interest expense on note payable to our principal stockholder																																						-543,000	-729,000
income before income tax benefit																																						17,922,500	126,520,000
revenue																																																							35,000						50,000	3,131,000			93,000											20,000					10,000					100,000
operating expenses:
product manufacturing																																								3,704,000	7,532,000	51,754,000	8,115,000	5,691,000	1,882,000
total operating expenses																																								19,124,000	20,013,000	272,863,000	26,003,000	24,051,000	21,738,000	30,103,000	38,266,000	69,846,000	41,411,000	46,617,000	44,762,000	41,585,000	36,437,000	33,486,000	35,522,000	44,054,000	33,933,000	30,579,000	32,773,000	39,186,000	38,051,000	1,814,898,000	32,093,000	42,540,000	37,356,000	40,601,000		55,819,000	42,767,000	53,386,000	57,806,000		81,755,000	69,080,000	80,864,000	74,085,000		79,067,000	75,569,000	75,393,000	77,338,000		71,798,000	61,134,000	55,777,000	45,088,000		35,046,000	32,862,000	27,567,000	22,647,000		21,696,000	20,503,000	18,382,000
in-process research and development costs																																																														19,726,000
goodwill impairment																																																														151,428,000
deemed dividend related to beneficial conversion feature of convertible preferred stock																																																														-22,260,000																															-4,955,500	-19,210,000
accretion on redeemable preferred stock																																																														-952,000																																	4,000
net loss applicable to common stockholders																																														-40,485,250	-36,520,000	-73,365,000	-52,056,000	-53,583,000	-50,818,000	-46,124,000	-40,965,000	-51,781,000	-42,834,000	-36,578,000	-38,173,000	-36,397,000	-38,402,000	-44,480,000	-41,525,000		-38,306,000	-45,303,000	-42,251,000	-44,700,000		-59,533,000	-45,555,000	-55,604,000	-59,412,000		-83,295,000	-68,496,000	-79,826,000	-71,421,000		-75,013,000	-73,047,000	-71,989,000	-73,141,000		-71,268,000	-60,970,000	-54,751,000	-43,559,000		-33,291,000	-31,730,000	-27,155,000	-22,162,000		-21,150,000	-39,398,000	-18,241,000
shares used to compute basic and diluted net loss per share applicable to common stockholders																																														95,333	394,163	380,770	368,784	12,702	296,386	284,044	280,058	16,244	190,534	159,859	143,154	181	122,130	121,708	121,057		424	113,528	113,116	113,095		2,132	108,779	102,322	102,030		66	101,647	101,427	101,409		6,594	73,520	73,421	73,388		1,252	49,731	49,638	49,787		3,498	43,460	32,777
interest expense on senior convertible notes and facility financing obligation																																																		-2,513,000	-4,323,000
interest expense on senior convertible notes																																																				-2,866,000	-2,863,000	-2,861,000	-2,859,000	-2,844,000	-2,575,000	-2,849,000	-2,845,000	-2,834,000	-2,413,000	-20,266,000	-2,831,000	-1,876,000	-1,211,000	-1,210,000		-1,392,000	-1,130,000	-1,130,000	-1,115,000		-1,742,000	-124,000	-124,000	-337,000		-584,000	-778,000	-901,000	-1,145,000
income taxes																																																														-26,000																							-4,000	-1,000					-1,000
income before benefit from income taxes																																																														-1,816,241,000
net income applicable to common stockholders																																																														-1,839,479,000
shares used to compute basic and diluted net income per share applicable to common stockholders
in—process research and development costs
net income per share	-0.05	-0.05	0.03		0.04	0.03	0.04	-0.01	0.04	0.01	0.01	-0.02	-0.04	-0.07	-0.06	-0.11	-0.1	-0.11	-0.02	-0.14	-0.05	-0.12	-0.05	-0.05	-0.04	-0.07	-0.05	-0.07	-0.08	-0.04	-0.16	-0.16	-0.25	-0.29	-0.31	-0.35	-0.17	1.21	0.26	-0.07	-0.06	-0.68	-0.08	-0.07	-0.08	-0.09	-0.09	-0.19	-0.14	-0.16	-0.17	-0.16	-0.15	-0.23	-0.22	-0.23	-0.27	-0.3	-0.31	-0.37	-0.34		-0.33	-0.4	-0.37	-0.4		-0.53	-0.42	-0.54	-0.58		-0.81	-0.67	-0.79	-0.7		-0.69	-0.99	-0.98	-1		-1.32	-1.23	-1.1	-0.87		-0.64	-0.73	-0.83
basic and diluted																																																																																											-0.68		-0.823	-1.4	-0.91
shares used to compute basic and diluted net loss per share:
basic and diluted																																																																																											32,764		5,671.75	28,051	19,975
income tax provision
research & development																																																																																															14,311,000
general & administrative																																																																																															4,071,000
basic and diluted – pro forma																																																																																															-0.73
shares used to compute net loss per share:
basic and diluted																																																																																											32,764		5,671.75	28,051	19,975

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30

assets
current assets:
cash and cash equivalents	52,834,000	74,882,000	127,392,000	57,006,000	47,312,000	46,339,000	62,373,000	96,643,000	193,272,000	238,480,000	83,016,000	86,184,000	85,869,000	69,767,000	54,308,000	35,507,000	67,243,000	124,184,000	51,740,000	62,522,000	247,833,000	67,005,000	52,398,000	63,222,000	38,868,000	29,906,000	30,173,000	7,968,000	34,530,000	71,157,000	10,446,000	26,178,000	26,706,000	43,946,000	20,092,000	43,384,000	47,978,000	22,895,000	35,530,000	63,733,000	27,653,000	59,074,000	32,928,000	107,187,000	120,844,000	120,841,000	172,465,000	41,214,000	35,759,000	70,790,000	93,803,000	28,529,000	28,005,000	61,840,000	1,765,000	31,639,000	56,355,000	2,681,000	22,786,000	24,770,000	46,912,000	66,061,000	97,928,000	28,358,000	29,052,000		53,918,000	31,328,000	27,114,000		31,582,000	180,454,000	269,079,000	368,285,000	152,298,000	216,429,000	262,753,000	319,555,000	43,086,000	27,056,000	45,889,000		69,238,000	19,552,000	22,089,000	78,987,000	103,871,000	37,373,000
short-term investments	81,027,000	96,464,000	132,643,000	121,979,000	134,229,000	150,917,000	189,215,000	151,118,000	107,457,000	56,619,000	58,000,000	58,163,000	80,273,000	101,079,000	110,738,000	118,649,000	95,203,000	79,932,000	87,312,000	99,970,000	28,962,000					19,978,000	19,885,000	24,909,000	24,764,000
accounts receivable	28,137,000	38,367,000	17,383,000	27,142,000	28,900,000	11,804,000	18,184,000	23,346,000	19,912,000	14,901,000	21,822,000	27,789,000	19,714,000	16,801,000	23,493,000	15,030,000	9,823,000	4,994,000	9,445,000	6,305,000	3,573,000	4,218,000	4,135,000	3,366,000	5,032,000	3,513,000	4,093,000	4,974,000	3,759,000	4,017,000	2,752,000	2,848,000	1,550,000	2,789,000	1,804,000	1,312,000	438,000	302,000	3,137,000
inventory	49,166,000	35,313,000	26,972,000	28,491,000	28,892,000	27,886,000	26,663,000	24,753,000	26,442,000	28,545,000	27,117,000	25,290,000	21,998,000	21,772,000	18,273,000	20,573,000	8,044,000	7,152,000	7,482,000	7,482,000	5,050,000	4,973,000	4,881,000	3,823,000	3,231,000	4,155,000	3,692,000	3,963,000	3,720,000	3,597,000	2,785,000	3,676,000	3,891,000	2,657,000	3,129,000	3,172,000	3,698,000	2,331,000	5,124,000	2,866,000			23,402,000	19,816,000	16,789,000	9,670,000
prepaid expenses and other current assets	39,996,000	46,553,000	54,447,000	44,409,000	34,404,000	31,360,000	31,229,000	30,080,000	36,019,000	34,848,000	35,620,000	32,807,000	15,445,000	25,477,000	11,569,000	3,717,000	3,952,000	3,482,000	3,227,000	3,624,000	2,766,000	3,122,000	4,616,000	1,856,000	1,901,000	2,889,000	3,584,000	2,704,000	2,392,000	2,556,000	3,015,000	2,570,000	2,354,000	3,010,000	3,061,000	2,563,000	3,508,000	4,364,000	4,534,000	1,423,000	2,807,000	4,018,000	13,227,000	14,076,000	16,375,000	20,206,000	20,253,000	3,696,000	3,640,000	5,485,000	5,228,000	3,183,000	3,830,000	4,520,000	21,082,000	18,356,000	3,004,000	2,625,000	2,960,000	1,593,000	2,479,000	2,849,000	3,309,000	2,451,000	3,217,000		5,247,000	4,533,000	4,907,000		7,709,000	7,253,000	8,004,000	9,596,000	11,876,000	10,664,000	13,714,000	10,650,000	11,702,000	6,952,000	5,907,000		3,451,000	2,457,000	3,027,000	3,265,000	2,046,000	2,653,000
total current assets	251,160,000	291,579,000	358,837,000	279,027,000	273,737,000	268,306,000	327,664,000	325,940,000	383,102,000	373,393,000	225,575,000	230,233,000	223,299,000	234,896,000	218,381,000	193,476,000	184,265,000	219,744,000	159,206,000	179,903,000	288,342,000	79,476,000	66,346,000	72,583,000	49,348,000	60,757,000	61,743,000	49,834,000	69,692,000	81,854,000	19,525,000	35,799,000	35,028,000	57,216,000	28,629,000	50,931,000	56,094,000	77,488,000	48,604,000	90,764,000	44,143,000	76,654,000	71,236,000	145,827,000	158,290,000	201,153,000	193,521,000	44,910,000	39,399,000	76,275,000	99,329,000	32,162,000	32,285,000	66,810,000	23,197,000	50,345,000	59,709,000	5,821,000	27,024,000	26,860,000	50,614,000	73,954,000	102,028,000	33,223,000	34,757,000		63,314,000	38,500,000	35,136,000		102,942,000	187,707,000	277,083,000	378,712,000	219,220,000	298,610,000	383,209,000	449,547,000	62,713,000	58,851,000	109,540,000		187,106,000	45,448,000	72,159,000	95,881,000	112,417,000	43,913,000
restricted cash	747,000	745,000	743,000	741,000	739,000	737,000	735,000	732,000													158,000	158,000	316,000	316,000	316,000	316,000	316,000	5,316,000	527,000	527,000	527,000	527,000	527,000	4,409,000																																																	18,000	18,000	585,000	583,000	581,000	579,000
long-term investments		5,012,000	26,226,000	22,240,000	16,681,000	5,482,000	16,796,000	13,398,000	3,726,000	7,155,000	3,271,000	2,282,000	492,000	1,961,000	12,728,000	32,596,000	70,542,000	56,619,000	42,059,000	38,950,000	1,480,000
property and equipment	82,554,000	82,423,000	82,652,000	82,965,000	83,781,000	85,365,000	85,339,000	85,144,000	83,620,000	84,220,000	80,411,000	69,510,000	54,837,000	45,126,000	41,182,000	37,918,000	41,453,000	36,612,000	30,848,000	28,139,000	26,507,000	25,867,000	25,736,000	26,187,000	26,517,000	26,778,000	27,126,000	27,146,000	25,750,000	25,602,000	25,632,000	26,036,000	26,481,000	26,922,000
goodwill	67,595,000	67,595,000	1,931,000	1,931,000	1,931,000	1,931,000	1,931,000	1,931,000	1,931,000	1,931,000	1,931,000	1,931,000	1,998,000	2,428,000	3,067,000	2,900,000
developed technology - on-body infusor	185,708,000	190,027,000
ipr&d - readyflow formulation	129,600,000	129,600,000
other intangible assets	5,024,000	5,072,000	5,120,000	5,169,000	5,217,000	5,265,000	5,313,000
other assets	22,015,000	20,129,000	19,131,000	19,624,000	28,055,000	26,757,000	26,422,000	15,658,000	7,447,000	7,426,000	8,047,000	8,353,000	16,378,000	9,718,000	17,310,000	17,507,000	12,058,000	8,186,000	6,094,000	5,799,000	3,053,000	3,265,000	3,599,000	4,011,000	4,347,000	6,190,000				249,000	199,000	320,000	368,000	437,000	480,000	523,000	609,000	648,000	702,000	1,248,000	1,096,000	1,009,000	1,831,000	2,025,000	2,027,000	848,000	2,114,000	7,400,000	8,437,000	5,516,000	10,227,000	230,000	230,000	230,000	230,000	230,000	230,000	230,000	230,000	230,000	230,000	317,000	404,000	584,000	584,000		584,000	555,000	10,548,000		550,000	549,000	549,000	548,000	547,000	546,000	361,000	362,000	359,000	288,000	287,000		282,000	203,000	203,000	61,000	50,000	51,000
total assets	744,403,000	792,182,000	494,640,000	411,697,000	410,141,000	393,843,000	464,200,000	443,836,000	480,879,000	475,198,000	320,328,000	313,422,000	298,137,000	295,282,000	293,837,000	285,797,000	308,318,000	321,161,000	238,207,000	252,791,000	319,382,000	108,608,000	95,681,000	102,781,000	80,212,000	93,725,000	95,140,000	81,795,000	100,961,000	107,705,000	45,356,000	62,155,000	61,877,000	84,575,000	56,483,000	79,374,000	85,185,000	107,063,000	96,131,000	139,434,000			278,014,000	352,551,000																						247,397,000				282,459,000												228,371,000
liabilities and stockholders' deficit
current liabilities:
accounts payable	16,144,000	9,034,000	7,269,000	10,257,000	5,041,000	6,792,000	6,444,000	9,556,000	7,149,000	9,580,000	16,754,000	17,127,000	13,889,000	11,052,000	9,871,000	7,823,000	8,702,000	6,956,000	9,528,000	7,486,000	6,706,000	5,582,000	5,797,000	5,821,000	6,731,000	4,789,000	11,664,000	7,533,000	6,978,000	5,379,000	5,815,000	9,237,000	4,976,000	6,984,000	5,283,000	6,541,000	1,519,000	3,263,000	5,093,000	2,849,000	582,000	15,599,000	4,444,000	5,190,000	3,302,000	7,394,000	17,389,000	5,086,000	3,638,000	3,860,000	7,786,000	5,419,000	3,604,000	4,555,000	3,166,000	5,817,000	2,661,000	4,624,000	1,598,000	1,600,000	5,360,000	3,294,000	6,372,000	2,365,000	8,766,000		8,801,000	11,171,000	14,222,000		19,992,000	30,084,000	24,399,000	35,463,000	36,738,000	5,653,000	10,123,000	10,715,000	6,673,000	2,586,000	4,008,000		5,407,000	4,621,000	5,095,000	3,477,000	1,429,000	1,840,000
accrued expenses and other current liabilities	58,598,000	64,628,000	31,419,000	30,915,000	40,103,000	40,293,000	37,386,000	40,952,000	42,291,000	42,036,000	32,098,000	36,833,000	32,995,000	35,553,000	30,350,000	33,184,000	27,131,000	27,419,000	20,829,000	22,406,000	27,586,000	19,707,000	15,814,000	14,706,000	18,326,000	15,904,000	14,298,000	16,452,000	18,064,000	15,022,000	13,434,000	14,075,000	15,930,000	12,449,000	12,492,000	9,076,000	10,657,000	7,937,000	14,164,000	10,252,000	8,077,000	7,929,000	14,081,000	13,930,000	12,381,000	26,206,000	27,269,000	20,579,000	15,006,000	21,634,000	21,553,000	26,984,000	26,379,000	25,777,000	48,598,000	49,624,000	31,746,000	20,736,000	15,715,000	19,958,000	19,035,000	14,840,000	19,193,000	19,824,000	17,534,000		19,624,000	27,718,000	25,937,000		36,087,000	31,874,000	31,048,000	32,095,000	36,109,000	52,758,000	45,730,000	34,244,000	31,034,000	24,548,000	20,249,000		13,553,000	11,567,000	7,618,000	8,194,000	6,382,000	4,835,000
senior convertible notes – current		36,280,000	36,224,000	36,166,000	36,109,000																																										99,120,000
liability for sale of future royalties – current	14,010,000	14,298,000	13,841,000	13,344,000	12,802,000	12,283,000	11,755,000	12,149,000	10,537,000	9,756,000
contingent consideration - current	23,877,000	21,132,000
financing liability – current	10,407,000	10,328,000	10,254,000	10,190,000	10,125,000	10,062,000	9,998,000	9,935,000	9,872,000	9,809,000	9,747,000	9,686,000	9,626,000
deferred revenue – current	11,525,000	15,331,000	10,123,000	10,954,000	11,757,000	12,407,000	6,518,000	7,420,000	7,601,000	9,085,000	3,670,000	3,489,000	2,316,000
total current liabilities	134,561,000	171,031,000	109,130,000	111,826,000	115,937,000	81,837,000	72,101,000	80,012,000	99,896,000	104,125,000	96,374,000	96,966,000	81,853,000	67,296,000	59,597,000	59,564,000	53,494,000	48,349,000	50,033,000	60,429,000	73,116,000	73,705,000	106,124,000	67,939,000	68,248,000	65,618,000	64,287,000	76,978,000	77,868,000	75,241,000	59,627,000	74,901,000	80,669,000	87,597,000	91,468,000	85,869,000	93,049,000	92,051,000	105,832,000	289,706,000	249,211,000	268,319,000	267,307,000	342,254,000	380,753,000	403,353,000	293,778,000	119,233,000	44,515,000	127,794,000	217,169,000	266,782,000	264,211,000	144,775,000	51,764,000	55,441,000	34,407,000	25,360,000	17,313,000	21,558,000	24,395,000	18,134,000	25,565,000	22,189,000	26,300,000		28,425,000	38,889,000	40,159,000		56,079,000	61,958,000	55,447,000	67,558,000	72,847,000	58,411,000	55,853,000	44,959,000	87,707,000	27,134,000	24,257,000		18,960,000	16,188,000	14,086,000	13,044,000	9,184,000	8,048,000
liability for sale of future royalties – long term	136,561,000	136,985,000	136,913,000	137,230,000	137,420,000	137,362,000	137,140,000	135,365,000	137,418,000	136,054,000
financing liability – long term	92,784,000	93,092,000	93,310,000	93,476,000	93,665,000	93,877,000	94,005,000	94,094,000	94,207,000	94,319,000	94,375,000	94,395,000	94,441,000
deferred revenue – long term	38,905,000	39,977,000	48,194,000	45,472,000	47,360,000	51,160,000	65,150,000	66,116,000	67,741,000	69,794,000	69,469,000	60,248,000	45,659,000
recognized loss on purchase commitments – long term	64,635,000	65,952,000	65,956,000	66,076,000	60,713,000	58,204,000	62,638,000	60,183,000	60,287,000	60,942,000	50,534,000	56,063,000	59,829,000
operating lease liability	10,281,000	10,689,000	10,258,000	10,656,000	11,141,000	11,645,000	12,167,000	3,272,000	3,645,000	3,925,000	4,289,000	4,646,000	4,879,000	5,343,000	5,666,000	5,928,000	826,000	1,040,000	798,000	564,000	869,000	1,202,000	1,523,000	1,843,000	2,155,000	2,514,000
contingent consideration – long term	5,146,000	5,114,000
milestone liabilities	2,003,000	2,003,000	2,003,000	2,003,000	2,523,000	2,523,000	2,813,000	2,813,000	3,452,000	3,452,000	3,772,000	3,772,000	4,524,000	4,524,000	4,524,000	4,524,000
term loan	318,722,000	318,361,000	73,428,000
total liabilities	803,598,000	843,204,000	539,192,000	466,739,000	468,759,000	472,659,000	674,126,000	669,616,000	710,849,000	721,366,000	572,107,000	573,909,000	553,533,000	545,820,000	531,514,000	532,853,000	540,382,000	530,510,000	422,895,000	436,342,000	493,004,000	289,027,000	282,101,000	282,491,000	278,262,000	284,251,000	279,846,000	277,794,000	288,965,000	282,787,000	250,797,000	268,774,000	285,085,000	299,307,000	307,498,000	300,617,000	283,910,000	290,656,000	334,818,000	506,011,000	466,736,000	476,741,000	402,583,000	468,026,000	457,053,000	468,209,000	427,496,000	282,683,000	207,017,000	289,359,000	455,330,000	364,786,000	362,002,000	361,993,000	486,579,000	484,767,000	528,806,000	513,205,000	504,824,000	473,740,000	458,253,000	462,788,000	486,588,000	377,219,000	344,197,000		291,060,000	286,395,000	242,537,000		168,207,000	173,962,000	167,329,000	179,343,000	184,512,000	169,958,000	167,283,000	156,250,000	87,731,000	27,158,000	24,281,000		18,996,000	16,231,000	14,134,000	13,120,000	9,242,000	8,178,000
commitments and contingencies
stockholders' deficit:
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2026 or december 31, 2025
common stock	3,089,000	3,078,000	3,070,000	3,063,000	3,039,000	3,029,000	2,753,000	2,740,000	2,703,000	2,700,000	2,695,000	2,682,000	2,643,000	2,638,000	2,632,000	2,573,000	2,524,000	2,515,000	2,502,000	2,496,000	2,491,000	2,421,000	2,309,000	2,289,000	2,131,000	2,118,000	2,064,000	1,894,000	1,878,000	1,870,000	1,594,000	1,456,000	1,260,000	1,192,000	1,047,000	1,046,000	958,000	4,784,000	4,784,000	4,777,000	4,290,000	4,287,000	4,182,000	4,121,000	4,090,000	4,061,000	4,055,000	3,964,000	3,869,000	3,697,000	3,100,000	3,012,000	2,894,000	2,860,000	1,998,000	1,993,000	1,678,000	1,315,000	1,313,000	1,309,000	1,307,000	1,278,000	1,234,000	1,137,000	1,134,000		1,128,000	1,036,000	1,020,000		1,017,000	1,016,000	1,014,000	1,014,000	736,000	735,000	734,000	734,000	499,000	496,000	496,000		501,000	328,000	327,000	327,000	327,000	200,000
additional paid-in capital	3,150,295,000	3,141,741,000	3,132,249,000	3,128,631,000	3,125,830,000	3,118,865,000	2,995,974,000	2,992,271,000	2,986,104,000	2,980,539,000	2,975,891,000	2,968,917,000	2,969,225,000	2,964,293,000	2,960,419,000	2,936,667,000	2,922,555,000	2,918,205,000	2,914,818,000	2,911,535,000	2,885,946,000	2,866,303,000	2,834,003,000	2,829,478,000	2,801,044,000	2,799,278,000	2,790,890,000	2,769,396,000	2,765,020,000	2,763,067,000	2,723,232,000	2,698,028,000	2,658,957,000	2,638,992,000	2,570,072,000	2,566,960,000	2,554,230,000	2,549,212,000	2,548,090,000	2,546,727,000	2,510,367,000	2,508,633,000	2,457,482,000	2,434,777,000	2,424,347,000	2,416,967,000	2,413,621,000	2,371,487,000	2,362,129,000	2,261,996,000	2,072,006,000	2,036,640,000	1,996,185,000	1,991,379,000	1,774,893,000	1,763,939,000	1,694,658,000	1,620,535,000	1,616,981,000	1,614,018,000	1,611,373,000	1,587,858,000	1,553,763,000	1,552,335,000	1,547,077,000		1,541,223,000	1,478,908,000			1,463,191,000	1,456,556,000	1,449,519,000	1,444,125,000	1,184,914,000	1,180,523,000	1,175,540,000	1,170,602,000	778,053,000	772,536,000	768,074,000		764,529,000	590,530,000	592,414,000	592,999,000	595,531,000	435,240,000
accumulated other comprehensive income	-4,000	115,000	137,000	1,257,000	1,174,000	1,109,000	588,000				443,000	443,000																																		-14,000				-4,000				-6,000	-8,000	-9,000	-3,000	44,000	45,000	38,000	86,000	74,000			-272,000		-107,000	-119,000	354,000														8,000	8,000	7,000
accumulated deficit	-3,212,575,000	-3,195,956,000	-3,180,008,000	-3,187,993,000	-3,188,661,000	-3,201,819,000	-3,209,241,000	-3,220,791,000	-3,218,777,000	-3,229,407,000	-3,230,808,000	-3,232,529,000	-3,227,264,000	-3,217,469,000	-3,199,522,000	-3,185,090,000	-3,156,067,000	-3,130,069,000	-3,102,008,000	-3,097,582,000	-3,062,059,000	-3,049,143,000	-3,022,732,000	-3,011,477,000	-3,001,225,000	-2,991,903,000	-2,977,640,000	-2,967,270,000	-2,954,883,000	-2,940,000,000	-2,930,249,000	-2,906,085,000	-2,883,410,000	-2,854,898,000	-2,822,114,000	-2,789,228,000	-2,753,889,000	-2,737,565,000	-2,791,540,000	-2,918,060,000	-2,888,102,000	-2,863,229,000	-2,586,214,000	-2,554,353,000	-2,525,447,000	-2,494,784,000
total stockholders' deficit	-59,195,000	-51,022,000	-44,552,000	-55,042,000	-58,618,000	-78,816,000	-209,926,000	-225,780,000	-229,970,000	-246,168,000	-251,779,000	-260,487,000	-255,396,000	-250,538,000	-237,677,000	-247,056,000	-232,064,000	-209,349,000	-184,688,000	-183,551,000	-173,622,000	-180,419,000	-186,420,000	-179,710,000	-198,050,000	-190,526,000	-184,706,000	-195,999,000	-188,004,000	-175,082,000	-205,441,000	-206,619,000	-223,208,000	-214,732,000	-251,015,000
total liabilities and stockholders' deficit	744,403,000	792,182,000	494,640,000	411,697,000	410,141,000	393,843,000	464,200,000	443,836,000	480,879,000	475,198,000	320,328,000	313,422,000	298,137,000	295,282,000	293,837,000	285,797,000	308,318,000	321,161,000	238,207,000	252,791,000	319,382,000	108,608,000	95,681,000	102,781,000	80,212,000	93,725,000	95,140,000	81,795,000	100,961,000	107,705,000	45,356,000	62,155,000	61,877,000	84,575,000	56,483,000
senior convertible notes						36,051,000	227,941,000	227,577,000	227,214,000	226,851,000	226,487,000	226,124,000	225,761,000	225,397,000	225,034,000	224,670,000	224,307,000	223,944,000	223,580,000	223,217,000	222,855,000	5,000,000	5,000,000	5,000,000	5,000,000	5,000,000	7,437,000	19,031,000	19,065,000	19,099,000	19,133,000	19,161,000	24,368,000	24,411,000	27,657,000	27,649,000	27,642,000	27,635,000		27,623,000	27,618,000				99,593,000	99,355,000		98,889,000	98,662,000		114,897,000	114,744,000	114,593,000	114,443,000	211,673,000	211,184,000	210,946,000	210,642,000	210,308,000	209,979,000	209,655,000	209,335,000	209,023,000	113,030,000	112,897,000	112,765,000	112,635,000	112,506,000	112,378,000	112,253,000	112,128,000	112,004,000	111,882,000	111,761,000	111,641,000	111,523,000	111,406,000	111,267,000
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of december 31, 2025 or december 31, 2024
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of september 30, 2025 or december 31, 2024
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of june 30, 2025 or december 31, 2024
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2025 or december 31, 2024
recognized loss on purchase commitments – current									2,446,000	3,859,000	14,105,000	13,164,000	11,360,000
midcap credit facility – current									20,000,000	20,000,000	20,000,000	16,667,000	11,667,000
midcap credit facility – long term									8,105,000	13,019,000	17,921,000	22,811,000
mann group convertible note									8,829,000	8,829,000	8,829,000	8,829,000	8,829,000		8,829,000	8,829,000
accrued interest – mann group convertible note									55,000	56,000	57,000	55,000	54,000
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of december 31, 2024 or 2023
financing lease liability							171,000	184,000
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of september 30, 2024 or december 31, 2023
other intangible asset								1,033,000	1,053,000	1,073,000	1,093,000	1,113,000	1,133,000	1,153,000	1,169,000	1,400,000
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of june 30, 2024 or december 31, 2023
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2024 or december 31, 2023
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of december 31, 2023 and 2022
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of september 30, 2023 and december 31, 2022
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of june 30, 2023 and december 31, 2022
midcap credit facility													27,704,000	39,264,000	39,155,000	39,047,000	38,939,000		38,723,000	38,614,000	49,406,000
undesignated preferred stock, 0.01 par value – 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2023 and december 31, 2022
accumulated other comprehensive loss															-1,206,000	-1,206,000	-1,076,000									-19,000	-20,000	-19,000	-19,000	-19,000	-18,000	-18,000	-15,000	-18,000	-20,000	-21,000	-24,000	-24,000	-21,000	-21,000	-19,000	-20,000	-19,000	-20,000	-21,000		-11,000	-4,000	-4,000		-9,000	-8,000	-8,000											-1,000
financing liability — current														9,565,000	9,525,000	9,470,000	9,410,000	6,977,000
deferred revenue — current														1,733,000	1,786,000	1,667,000	1,307,000	827,000	14,016,000	20,126,000	25,880,000	33,275,000	28,867,000	32,184,000	30,840,000	32,503,000
recognized loss on purchase commitments — current														9,393,000	8,065,000	7,420,000	6,944,000	6,170,000	5,660,000	5,538,000	8,274,000	11,080,000	10,267,000	9,841,000	7,250,000	7,394,000												5,093,000
promissory notes														8,829,000			18,425,000	18,425,000				63,027,000	70,025,000	70,024,000	70,022,000	70,020,000	70,019,000
accrued interest — promissory notes														55,000		86,000	520,000	404,000				4,150,000	5,854,000	4,538,000	3,259,000	2,002,000
financing liability — long term														94,512,000	94,484,000	94,447,000	93,463,000	93,525,000
recognized loss on purchase commitments — long term														62,916,000	62,173,000	65,996,000	72,400,000	76,659,000	79,653,000	83,179,000	80,797,000	84,208,000	84,529,000	81,027,000	82,987,000	84,639,000												95,942,000
deferred revenue — long term														37,684,000	31,996,000	29,762,000	26,116,000	19,543,000	1,552,000	1,589,000	1,626,000	1,662,000	1,699,000	4,860,000	1,772,000	8,344,000
deposits from customer																	7,054,000	4,950,000	5,007,000	5,317,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2022 and 2021
accrued interest — promissory note															56,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of september 30, 2022 and december 31, 2021
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of june 30, 2022 and december 31, 2021
milestone rights liability																	4,838,000	4,838,000	4,838,000	4,839,000	5,926,000	5,926,000	5,926,000	5,926,000	5,926,000	7,263,000	7,263,000	7,201,000	7,201,000	7,201,000	7,202,000	7,201,000	7,201,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2022 and december 31, 2021
paycheck protection program loan — current																						4,061,000
long-term midcap credit facility																		38,833,000				49,335,000		39,304,000	38,893,000	38,851,000
2024 convertible notes
paycheck protection program loan — long term																						812,000	1,421,000	2,030,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2021 and 2020
ppp loan — current																				4,873,000	4,670,000
mann group promissory notes																			18,425,000	18,425,000	53,453,000
accrued interest — mann group promissory notes																			286,000	169,000	4,753,000
ppp loan — long term																					203,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of september 30, 2021 and december 31, 2020
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of june 30, 2021 and december 31, 2020
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2021 and december 31, 2020
short-term note payable																									5,101,000	5,028,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2020 and 2019
short-term notes payable																							45,379,000	5,387,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of september 30, 2020 and december 31, 2019
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of june 30, 2020 and december 31, 2019
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding as of march 31, 2020 and december 31, 2019
facility financing obligation																												8,974,000	11,385,000	11,298,000	14,202,000	38,002,000	43,654,000	52,745,000	57,942,000	57,484,000	71,795,000	71,339,000	70,888,000	75,452,000	75,010,000	74,582,000	74,163,000	73,757,000	73,368,000	72,995,000		37,744,000	25,871,000	102,300,000	72,933,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2019 and 2018
right-of-use and other assets																											6,271,000	4,815,000	5,519,000
senior convertible notes - current																											2,520,000
deferred revenue - current																											32,212,000	32,370,000	32,384,000
recognized loss on purchase commitments - current																											3,593,000	11,649,000	9,057,000	6,657,000	16,081,000	13,191,000	15,859,000	12,131,000	12,480,000		6,984,000		8,340,000
credit facility																											38,798,000
accrued interest - promissory notes																											807,000
recognized loss on purchase commitments - long term																											85,858,000	81,978,000	85,344,000	91,642,000	84,362,000	88,346,000	96,694,000	97,585,000	99,769,000		95,062,000		63,229,000
deferred revenue - long term																											2,631,000	8,399,000	15,867,000
operating lease liabilities																											2,746,000	3,094,000	3,615,000
note payable to related party																												71,981,000	72,036,000	72,089,000	72,143,000	72,196,000	72,247,000																		119,635,000	119,635,000	119,635,000	119,635,000	223,142,000	218,142,000	283,453,000	277,203,000	277,203,000	242,203,000	224,203,000	235,319,000	252,000,000	242,000,000	205,000,000	165,000,000	150,000,000	135,000,000	90,000,000
accrued interest - note payable to related party																												9,132,000	7,969,000	6,835,000	5,692,000	4,566,000	3,469,000
deferred costs from commercial product sales																																		405,000	543,000	500,000	472,000	309,000	279,000
deferred revenue																																		3,038,000					2,014,000
deferred payments from collaborations - current																														36,885,000
deferred payments from collaborations - long term																														10,680,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2018 and 2017
deferred payments from collaboration - current																															10,095,000	396,000	250,000	250,000	250,000		250,000
deferred payments from collaboration - long term																															2,638,000	2,403,000	437,000	500,000	563,000		687,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2018 and december 31, 2017
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2018 and december 31, 2017
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2018 and december 31, 2017
receivable from sanofi																																						30,557,000
asset held for sale																																						16,730,000
note payable to principal stockholder																																		79,666,000	79,666,000	79,666,000	49,521,000	49,521,000		49,521,000	49,521,000	49,521,000	49,521,000	49,521,000	49,521,000	49,521,000	49,521,000	49,521,000	49,521,000	49,521,000																													50,000,000
accrued interest - note payable to principal stockholder																																		2,347,000	1,173,000		9,995,000
warrant liability																																				605,000	752,000	7,381,000	4,871,000	18,056,000
milestone rights liability and other liabilities																																		7,201,000	7,202,000	7,202,000	7,202,000	8,845,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2017 and 2016
property and equipment - net																																			27,374,000		28,482,000		46,825,000
deferred revenue - net																																			3,021,000		1,844,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2017 and december 31, 2016
property and equipment—net																																				27,920,000																																																		66,511,000
liabilities and stockholders’ deficit
deferred revenue—net																																				2,592,000
deferred payments from collaboration—current																																				250,000
recognized loss on purchase commitments—current																																				9,926,000
accrued interest—note payable to principal stockholder
recognized loss on purchase commitments—long term																																				99,001,000
deferred payments from collaboration—long term																																				625,000
stockholders’ deficit:
undesignated preferred stock, 0.01 par value—10,000,000 shares authorized; no shares issued or outstanding at june 30, 2017 and december 31, 2016
total stockholders’ deficit																																				-221,243,000	-198,725,000	-183,593,000	-238,687,000	-366,577,000	-373,464,000	-350,329,000	-124,569,000	-115,475,000		-73,770,000	-40,678,000			-30,713,000	-167,722,000	-152,357,000	-146,806,000	-110,679,000	-276,248,000	-244,375,000	-277,386,000	-313,652,000	-280,810,000	-245,382,000	-203,501,000	-185,532,000	-181,439,000	-137,662,000
total liabilities and stockholders’ deficit																																				79,374,000	85,185,000	107,063,000	96,131,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2017 and december 31, 2016
deferred costs from collaboration																																								22,742,000
property and equipment — net																																						28,927,000		47,422,000	48,033,000	48,749,000	191,408,000	193,868,000	193,454,000	192,127,000	190,923,000	183,533,000	176,337,000	176,557,000	177,829,000	179,567,000	182,290,000	183,961,000	186,611,000	189,159,000	190,916,000	193,029,000	196,374,000	200,383,000	203,179,000	202,356,000	202,235,000	204,398,000	206,761,000		224,057,000	226,221,000	228,352,000		225,515,000	208,742,000	185,895,000	162,683,000	143,244,000	118,331,000	98,622,000	88,328,000	84,005,000	83,190,000	80,289,000
deferred revenue — net																																						3,419,000
deferred payments from collaboration																																						1,000,000	462,000	135,229,000	134,935,000	140,231,000	157,145,000	171,850,000	185,059,000	197,403,000
deferred sales from collaboration																																								26,882,000
accrued interest — note payable to principal stockholder																																						9,281,000
sanofi loan facility and loss share obligation																																							71,210,000		68,835,000	62,371,000	43,653,000	28,415,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or or outstanding at december 31, 2016 and 2015
note payable to our principal stockholder																																							49,521,000
senior convertible notes - long term																																							27,629,000
other liabilities																																							17,397,000	16,668,000	15,946,000	15,225,000	14,495,000	12,123,000	26,779,000	15,335,000	11,572,000	15,040,000	14,319,000	13,605,000	20,306,000																							24,000	24,000	24,000	24,000	24,000	24,000	24,000	24,000		36,000	43,000	48,000	76,000	58,000	130,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2016 and december 31, 2015
receivables from collaboration																																									144,000	23,000	1,679,000	4,748,000	4,282,000	50,436,000
purchase commitment loss — current																																								20,986,000
sanofi loan facility and profit/loss share obligation																																								69,978,000
non-current purchase commitment loss																																								52,515,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2016 and december 31, 2015
total																																								139,434,000	93,272,000	126,412,000	278,014,000	352,551,000	360,022,000	394,439,000	386,818,000	236,306,000	224,553,000	258,646,000	287,608,000	212,429,000	215,196,000	251,314,000	210,331,000	240,392,000	251,420,000	199,553,000	224,014,000	228,358,000	254,752,000	277,256,000	305,149,000	239,557,000	243,255,000		288,655,000	267,126,000	275,711,000		331,632,000	399,248,000	465,402,000	543,443,000	364,136,000	418,237,000	482,567,000	539,737,000	149,702,000	144,579,000	191,991,000		260,024,000	114,817,000	141,757,000	163,483,000	181,797,000	110,778,000
deferred product costs from collaboration																																									13,539,000	13,539,000	13,539,000	10,831,000
liabilities and stockholders’ equity
deferred product sales from collaboration																																									17,680,000	17,503,000	17,474,000	13,404,000	7,050,000
purchase commitment liabilities — current																																									12,927,000	12,475,000
net purchase commitments																																									55,605,000
stockholders’ equity
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2016 and december 31, 2015
inventory-current
state research and development credit exchange receivable — net of current portion																																														311,000			380,000	298,000	223,000	470,000	391,000	313,000				473,000	386,000	885,000	729,000	629,000	482,000	1,352,000	1,153,000		700,000	1,850,000	1,675,000		2,625,000	2,250,000	1,875,000	1,500,000	1,125,000	750,000	375,000	1,500,000	2,625,000	2,250,000	1,875,000			813,000
senior convertible notes — current
senior convertible notes — long term																																										27,613,000
purchase commitments — long term																																										53,692,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2015 and 2014
senior convertible notes-current																																												64,123,000
senior convertible notes-long term																																											27,607,000	35,713,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2015 and december 31, 2014
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2015 and december 31, 2014
deferred products costs from collaboration																																													6,251,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2015 and december 31, 2014
total stockholders’																																													-97,031,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2014 and 2013
state research and development tax credit exchange receivable – current																																															803,000
state research and development credit exchange receivable																																															260,000	463,000							293,000	658,000	565,000																										1,233,000	537,000	1,500,000		1,500,000
deferred up-front payment from collaboration agreement																																															150,000,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2014 and december 31, 2013
deficit accumulated during the development stage																																															-2,458,343,000	-2,421,824,000	-2,348,458,000	-2,296,402,000	-2,242,819,000	-2,192,001,000	-2,145,877,000	-2,104,912,000	-2,053,131,000	-2,010,298,000	-1,973,719,000	-1,935,546,000	-1,899,149,000	-1,860,747,000	-1,816,267,000	-1,774,742,000	-1,736,436,000	-1,691,133,000	-1,648,881,000	-1,604,182,000	-1,544,649,000	-1,499,094,000	-1,443,490,000	-1,384,078,000	-1,300,783,000	-1,232,286,000	-1,152,460,000	-1,081,039,000	-1,006,026,000	-932,979,000	-860,990,000	-787,849,000	-716,581,000	-655,611,000	-600,860,000	-557,301,000	-524,010,000	-492,280,000	-465,125,000	-442,963,000	-421,813,000	-401,625,000
share-based compensation liability																																																55,824,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2014 and december 31, 2013
total stockholders’ equity																																																-46,377,000	17,536,000																-100,942,000	-59,221,000	-2,405,000	-19,269,000	33,174,000	86,734,000	163,425,000	225,286,000	298,073,000	364,100,000	179,624,000	248,279,000	315,284,000	383,487,000	61,971,000	117,421,000	167,710,000	206,977,000	241,028,000	98,586,000	127,623,000	150,363,000	172,555,000	97,352,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2014 and december 31, 2013
state research and development credit exchange receivable — current																																																			298,000	450,000	450,000	450,000					765,000		674,000	674,000												831,000				2,418,000	918,000		1,044,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2012 and 2013
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2013 and december 31, 2012
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2013 and december 31, 2012
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2013 and december 31, 2012
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2011 and 2012
available-for-sale securities and certificate of deposit																																																							350,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2012 and december 31, 2011
available for sale securities and certificate of deposit																																																								350,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2012 and december 31, 2011
available for sale securities																																																									350,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2012 and december 31, 2011
marketable securities																																																										515,000	513,000	497,000	549,000	4,370,000	117,000	2,414,000	2,488,000		2,649,000	2,639,000	3,115,000		63,651,000				51,875,000	67,599,000	102,824,000	116,924,000	7,007,000	23,800,000	56,700,000		113,166,000	22,884,000	44,958,000	11,546,000	5,000,000	3,887,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2010 and 2011
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2011 and december 31, 2010
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2011 and december 31, 2010
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2011 and december 31, 2010
commitments and contingencies stockholders’ deficit:
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2009 and 2010
state research and development credit exchange — current																																																															674,000				1,500,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2010 and december 31, 2009
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2010 and december 31, 2009
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2010 and december 31, 2009
cash, cash equivalents and marketable securities																																																																		32,494,000				46,492,000												145,634,000
working capital																																																																		8,813,000				503,000												128,507,000
deferred compensation and other liabilities																																																																																		29,000
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2009 and december 31, 2008
undesignated preferred stock, 0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2009 and december 31, 2008
stockholders’ equity:
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2009 and december 31, 2008
additional paid—in capital																																																																					1,475,290,000
redeemable convertible preferred stock
state research and development credit exchange																																																																											3,171,000	3,918,000	3,918,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2008 and december 31, 2007
undesignated preferred stock, 0.01 par value —— 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2008 and december 31, 2007
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2008 and december 31, 2007
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2006 and 2007
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2007 and december 31, 2006
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2007 and december 31, 2006
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2007 and december 31, 2006
deferred compensation																																																																																					1,373,000		1,373,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at december 31, 2005 and 2006
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at september 30, 2006 and december 31, 2005
state research and development credit exchange receivable current																																																																																1,043,000
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at june 30, 2006 and december 31, 2005
undesignated preferred stock, 0.01 par value — 10,000,000 shares authorized; no shares issued or outstanding at march 31, 2006 and december 31, 2005
property, plant and equipment – net																																																																																			71,387,000		67,999,000		66,223,000	66,235,000
state research and development credit exchange receivable – net of current portion																																																																																			1,249,000		1,396,000		2,526,000
undesignated preferred stock, 0.01 par value—10,000,000 shares authorized; no shares issued or outstanding at september 30, 2005 and december 31, 2004
property, plant and equipment — net																																																																																				68,353,000
undesignated preferred stock, 0.01 par value—10,000,000 shares authorized; no shares issued or outstanding at june 30, 2005 and december 31, 2004
undesignated preferred stock, 0.01 par value-10,000,000 shares authorized; no shares issued or outstanding at march 31, 2005 and december 31, 2004
state r&d credit exchange receivable—current																																																																																						1,500,000
state r&d credit exchange receivable—net of current portion																																																																																						1,030,000
payable to stockholder
deferred compensation—current																																																																																						1,373,000
deferred compensation—net of current portion
series a redeemable convertible preferred stock, 0.01 par value—267,213 shares authorized, 267,212, issued and outstanding at december 31, 2003 and no shares authorized, issued and outstanding at december 31, 2004; aggregate liquidation value, 5,188 as of december 31, 2003
undesignated preferred stock, 0.01 par value—10,000,000 shares authorized; no shares issued or outstanding at december 31, 2003 and 2004
series b convertible preferred stock, 0.01 par value—192,618 shares authorized, issued and outstanding at december 31, 2003 and no shares authorized, issued and outstanding at december 31, 2004; aggregate liquidation value, 15,000 at december 31, 2003
series c convertible preferred stock issuable
series c convertible preferred stock subscriptions receivable
notes receivable from stockholders
notes receivable from officers
deferred compensation – net of current portion
series a redeemable convertible preferred stock, 0.01 par value—267,213 shares authorized; no shares issued and outstanding at september 30, 2004; 267,212, issued and outstanding at december 31 2003
series b convertible preferred stock, 0.01 par value—192,618 shares authorized; no shares issued and outstanding at september 30, 2004; 192,618 shares issued and outstanding at december 31, 2003
series c convertible preferred stock issuable - .01 par value...
undesignated preferred stock, 0.01 par value—10,000,000 shares authorized at september 30, 2004
note receivable from stockholders																																																																																							-1,490,000	-1,463,000
note receivable from officers
deferred compensation – current																																																																																								1,373,000
series a redeemable convertible preferred stock, 0.01 par value—267,213 shares authorized; 267,212, issued and outstanding at december 31 2003 and june 30, 2004, respectively; aggregate liquidation value, 5,188 as of december 31, 2003 and 5,248 as of june 30, 2004																																																																																								5,248,000
series b convertible preferred stock, 0.01 par value—192,618 shares authorized, issued and outstanding at december 31, 2003 and june 30, 2004, respectively; aggregate liquidation value, 15,000 at december 31, 2003 and june 30, 2004																																																																																								15,000,000
series c convertible preferred stock, .01 par value — 980,393 shares authorized; 980,392 shares issued and outstanding at june 30, 2004, aggregate liquidation value of 50,000 at june 30, 2004																																																																																								50,000,000

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2008-02-14	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2007-02-14	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30

cash flows from operating activities:
net income	-16,619,000	-15,948,000	7,985,000	668,000	13,158,000	7,422,000	11,550,000	-2,014,000	10,630,000																		-10,370,000	-12,387,000	-14,883,000					-32,784,000				53,974,000																																				-71,421,000					-73,141,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation	6,455,000	6,972,000	4,318,000	7,520,000	5,385,000	5,818,000	5,227,000	6,428,000	3,885,000
interest on liability for sale of future royalties	2,565,000	3,885,000	3,512,000	3,475,000	3,577,000	3,452,000	4,089,000	4,383,000	4,248,000
sold portion of royalty revenue	-3,275,000	-3,356,000	-3,332,000	-3,123,000	-3,000,000	-2,701,000	-2,709,000
write-off of inventory	1,075,000	2,062,000	3,277,000	4,592,000	466,000	1,946,000	291,000	589,000	1,029,000	915,000	300,000	943,000	2,416,000	834,000	917,000							0	0	0	496,000					420,000	1,013,000	177,000	602,000
noncash lease expense of right-of-use assets	532,000
depreciation and amortization	6,382,000	6,030,000	2,061,000	2,087,000	2,106,000	2,160,000	2,119,000	1,731,000	1,361,000	1,225,000	1,137,000	1,115,000	1,058,000		1,769,000	1,411,000	1,324,000																																							3,647,000	3,696,000	3,815,000	4,074,000	3,904,000	4,119,000	4,408,000	4,309,000	4,293,000	4,314,000	4,705,000	4,787,000	4,718,000	4,515,000	4,966,000	3,517,000	1,929,000	1,875,000	1,875,000	2,720,000	2,088,000	1,995,000	2,170,000	2,170,000	2,191,000	2,211,000	2,115,000	2,000,000	1,928,000	1,824,000	1,828,000	1,811,000	1,809,000	1,806,000
loss on foreign currency transactions	-1,318,000
net accretion of investments	-271,000	-402,000	-567,000	-759,000	-919,000		-1,656,000	-1,125,000	-984,000
change in fair value of contingent liability	2,777,000
amortization of debt discount and issuance costs	452,000	478,000	158,000	109,000	109,000	313,000	417,000	415,000	501,000	515,000	629,000	472,000	469,000
loss on settlement of debt	917,000
other	-62,000					-290,000	0	0	49,000	94,000	-188,000	-295,000	50,000									0	0	0	19,000	4,000			-1,000	-131,000	0	-4,000	110,000	-147,000	133,000			-698,000	0	21,000	696,000	45,000	1,000	1,000	-7,000	-3,000				5,000	-1,000	0	-2,000	2,000	3,000	-8,000	1,000			4,000	5,000	-1,000	1,000	-3,000	-3,000	0	2,000
change in deferred tax liability
changes in operating assets and liabilities:
accounts receivable	10,290,000	817,000	9,759,000	1,758,000	-17,096,000	6,380,000	5,162,000	-3,434,000	-5,456,000	7,366,000	5,967,000	-8,075,000	-2,913,000	6,692,000	-8,463,000	-5,207,000	-4,829,000	4,451,000	-3,140,000	-2,732,000	645,000	-83,000	-769,000	1,808,000	-1,661,000	580,000	881,000	-1,215,000	258,000	-1,265,000	96,000	-1,298,000	1,128,000	-985,000	-492,000	-874,000	-136,000	2,812,000
inventory	-14,928,000	797,000	-1,758,000	-4,191,000	-1,472,000	-3,169,000	-2,201,000	1,100,000	1,074,000	-2,343,000	-2,127,000	-4,236,000	-2,641,000	-4,333,000	1,383,000	-1,828,000	-892,000	-1,572,000	0	-2,432,000	-77,000	-92,000	-1,058,000	-592,000	428,000	-463,000	271,000	-243,000	-123,000	-1,232,000	-122,000	38,000	-1,836,000	-2,499,000	43,000	526,000	-1,367,000	2,793,000	-2,258,000			-12,702,000	-3,586,000	-3,027,000	-7,119,000
prepaid expenses and other current assets	6,557,000	2,328,000	-6,989,000	-2,327,000	-3,044,000	-132,000	-1,148,000	-2,020,000	-3,274,000	-905,000	-3,285,000	-7,657,000	2,426,000	-7,465,000	-7,852,000	235,000	-470,000	-255,000	397,000	-858,000	356,000	1,152,000	-2,658,000	364,000	988,000	695,000	-878,000	-314,000	164,000	459,000	-445,000	-216,000	656,000	51,000	-497,000	944,000	856,000	170,000	-3,111,000	1,384,000	1,211,000	6,506,000	849,000	2,299,000	3,831,000	47,000	-16,557,000	-56,000	1,845,000	-257,000	-2,045,000	647,000	690,000	16,462,000	-2,276,000	-16,096,000	365,000	335,000	-1,367,000	886,000	370,000	460,000	-858,000	766,000	455,000	1,575,000	-714,000	374,000	1,076,000	1,726,000	-456,000	751,000	1,592,000	1,592,000	3,880,000	-1,212,000	3,050,000	-3,064,000	-3,064,000	1,052,000	-4,750,000	-1,045,000	-2,863,000	407,000	-994,000	570,000	238,000	-1,219,000	607,000
other assets	-2,416,000	-383,000	-1,000	136,000	-1,661,000	-749,000	-612,000	-1,895,000	-314,000	298,000	-15,000			1,091,000	-127,000	-121,000	-320,000	301,000	-237,000	-105,000	-97,000	36,000	109,000	42,000	40,000					0	121,000	41,000	38,000	22,000	41,000	86,000	39,000	54,000	545,000	-152,000	-86,000	822,000	194,000	6,000	-872,000	-485,000	1,000											0	0	0	87,000	87,000				0	-29,000				-1,000	0	-1,000	-1,000	-1,000	-1,000	-185,000	1,000	1,000	-3,000	-71,000	-1,000	-2,000	-3,000	-79,000	0	-142,000	-11,000	1,000
accounts payable	7,110,000	-17,188,000	-2,988,000	5,216,000	-1,751,000	348,000	-3,112,000	2,407,000	-2,431,000	-7,175,000	-373,000	3,238,000	2,837,000	1,180,000	2,049,000	-878,000	1,745,000	-2,572,000	2,042,000	780,000	1,124,000	-215,000	-24,000	-910,000	1,942,000	-6,875,000	4,128,000	555,000	1,599,000	-436,000	-3,422,000	4,261,000	-2,008,000	1,701,000	-1,258,000	5,022,000	-1,665,000	-1,830,000	2,244,000	2,267,000	-14,799,000	11,111,000	-462,000	1,946,000	-4,182,000	-10,070,000	12,125,000	2,605,000	-1,038,000	858,000	-955,000	-50,000	-924,000	1,570,000	-2,770,000	2,957,000	-1,713,000	2,793,000	326,000	-229,000	-218,000	-4,252,000	3,775,000	-5,018,000	1,208,000	-2,377,000	-735,000	-65,000	-3,194,000	-2,118,000	-6,520,000	3,894,000	-9,876,000	-9,876,000	1,591,000	19,736,000	-4,470,000	-592,000	-592,000	4,042,000	4,088,000	-1,423,000	461,000	-1,421,000	786,000	-474,000	1,618,000	2,048,000	-411,000
accrued expenses and other current liabilities	-5,771,000	13,350,000	-761,000	-9,467,000	134,000	2,106,000	-3,046,000	-2,433,000	670,000	10,430,000	579,000	1,572,000	-5,975,000	2,212,000	-2,801,000	-644,000	510,000	5,343,000	256,000	-5,073,000	8,288,000	2,705,000	1,984,000	-3,223,000	1,880,000	3,632,000	-594,000	-1,876,000	2,336,000	1,689,000	-258,000	-1,857,000	2,675,000	43,000	3,372,000	-1,560,000	1,077,000	-6,227,000	3,912,000	2,175,000	488,000	-6,545,000	1,878,000	2,860,000	-10,660,000	5,279,000	312,000	3,389,000	-6,704,000	150,000	1,127,000	1,683,000	715,000	-21,823,000	3,590,000	31,420,000	1,888,000	5,184,000	-3,713,000	724,000	3,850,000	-3,458,000	-783,000	1,473,000	-4,786,000	3,424,000	-4,242,000	-650,000	-10,803,000	3,052,000	4,517,000	1,111,000	-2,285,000	-2,285,000	-5,244,000	-12,363,000	5,087,000	5,635,000	5,635,000	3,210,000	6,486,000	4,299,000	2,431,000	3,826,000	1,986,000	3,949,000	-576,000	1,812,000	1,547,000
deferred revenue	-4,878,000	-3,009,000	1,891,000	-2,691,000	-4,450,000	-8,101,000	-1,868,000	-1,806,000	-3,537,000	5,740,000	9,402,000	15,762,000	8,558,000	5,635,000	2,353,000	4,006,000	7,053,000	4,802,000	-6,147,000	-5,791,000	-7,431,000	4,371,000	-6,478,000	4,432,000	-8,235,000	6,004,000	-5,926,000	-7,481,000	686,000					17,000				1,405,000
operating lease liabilities	-939,000	0	46,000	53,000	-972,000	-885,000	-861,000	-314,000	-232,000	-607,000	-625,000	-467,000	-686,000	-324,000	-544,000	-1,869,000	-572,000	-768,000	187,000	-1,221,000	-333,000	775,000	-686,000	-677,000	-724,000	-608,000
net cash from operating activities	-5,365,000	-7,958,000	23,640,000	8,950,000	-6,377,000	22,644,000	9,331,000	3,833,000	6,703,000	21,678,000	8,664,000	2,596,000	1,156,000	-2,376,000	-28,073,000	-31,982,000	-18,248,000	-12,347,000	-15,184,000	-21,447,000	-12,731,000	235,000	-13,460,000	-3,684,000	-11,219,000	-5,107,000	-52,051,000	-19,728,000	-11,597,000	24,988,000	-13,919,000	-27,150,000	-21,650,000	-29,981,000	-23,270,000	-20,034,000	8,507,000	-12,752,000	-23,071,000	-11,509,000	-30,758,000	-22,551,000	-19,892,000	-17,809,000	3,020,000	-35,744,000	100,238,000	-23,418,000	-36,990,000	-34,051,000	-32,910,000	-29,744,000	-32,027,000	-28,098,000	-34,258,000	-25,018,000	-32,486,000	-20,355,000	-36,035,000	-36,743,000	-30,704,000	-38,972,000	-34,848,000	-36,336,000	-38,498,000	-37,377,000	-41,684,000	-44,353,000	-60,669,000	-70,243,000	-61,034,000	-65,754,000	-74,257,000	-74,257,000	-57,423,000	-60,273,000	-62,633,000	-64,817,000	-64,817,000	-55,055,000	-50,008,000	-47,408,000	-37,323,000	-30,467,000	-27,706,000	-22,760,000	-20,296,000	-17,643,000	-13,402,000
capital expenditures	-1,880,000	-1,994,000	-1,125,000	-1,117,000	-330,000	-2,896,000	-1,417,000	-2,972,000	-2,408,000	-5,874,000	-11,387,000	-16,869,000	-8,311,000	-5,096,000	-271,000	2,834,000	-5,056,000	-5,190,000	-4,246,000	-1,054,000	-976,000	-497,000	-4,000	-150,000	-150,000	-109,000	-963,000	-1,224,000	-269,000	0	0	0	0	0	0	0		0	0	0	-1,144,000	-316,000	-1,232,000	-4,534,000	-4,203,000	-4,963,000	-9,467,000	-8,258,000	-1,409,000	-6,166,000	-230,000	-132,000	-1,459,000	-65,000	-124,000	-125,000	-323,000	-155,000	-594,000	-4,116,000	-1,993,000	-3,935,000	-1,555,000	-2,363,000	-1,689,000	-2,173,000	-4,131,000	-6,926,000	-5,622,000	-10,156,000	-24,042,000	-23,275,000	-24,980,000	-24,980,000	-32,322,000	-19,820,000	-19,646,000	-6,474,000	-6,474,000	-6,542,000	-3,090,000	-5,035,000	-6,106,000	-6,741,000	-4,881,000	-2,154,000	-3,393,000	-2,263,000	-2,114,000
free cash flows	-7,245,000	-9,952,000	22,515,000	7,833,000	-6,707,000	19,748,000	7,914,000	861,000	4,295,000	15,804,000	-2,723,000	-14,273,000	-7,155,000	-7,472,000	-28,344,000	-29,148,000	-23,304,000	-17,537,000	-19,430,000	-22,501,000	-13,707,000	-262,000	-13,464,000	-3,834,000	-11,369,000	-5,216,000	-53,014,000	-20,952,000	-11,866,000	24,988,000	-13,919,000	-27,150,000	-21,650,000	-29,981,000	-23,270,000	-20,034,000		-12,752,000	-23,071,000	-11,509,000	-31,902,000	-22,867,000	-21,124,000	-22,343,000	-1,183,000	-40,707,000	90,771,000	-31,676,000	-38,399,000	-40,217,000	-33,140,000	-29,876,000	-33,486,000	-28,163,000	-34,382,000	-25,143,000	-32,809,000	-20,510,000	-36,629,000	-40,859,000	-32,697,000	-42,907,000	-36,403,000	-38,699,000	-40,187,000	-39,550,000	-45,815,000	-51,279,000	-66,291,000	-80,399,000	-85,076,000	-89,029,000	-99,237,000	-99,237,000	-89,745,000	-80,093,000	-82,279,000	-71,291,000	-71,291,000	-61,597,000	-53,098,000	-52,443,000	-43,429,000	-37,208,000	-32,587,000	-24,914,000	-23,689,000	-19,906,000	-15,516,000
cash flows from investing activities:
purchase of available-for-sale securities	-10,301,000	-13,723,000	-55,953,000	-44,023,000	-44,104,000									0	0	0	-5,000,000	0	0
proceeds from maturities of available-for-sale securities	30,906,000	71,496,000	42,020,000	51,396,000	50,396,000
purchase of property and equipment	-1,880,000	-1,994,000	-1,125,000	-1,117,000	-330,000	-2,896,000	-1,417,000	-2,972,000	-2,408,000	-5,874,000	-11,387,000	-16,869,000	-8,311,000	-5,096,000	-271,000	2,834,000	-5,056,000	-5,190,000	-4,246,000	-1,054,000	-976,000	-497,000	-4,000	-150,000	-150,000	-109,000	-963,000	-1,224,000	-269,000									0	0	0	-1,144,000	-316,000	-1,232,000	-4,534,000	-4,203,000	-4,963,000	-9,467,000	-8,258,000	-1,409,000	-6,166,000	-230,000	-132,000	-1,459,000	-65,000	-124,000	-125,000	-323,000	-155,000	-594,000	-4,116,000	-1,993,000	-3,935,000	-1,555,000	-2,363,000	-1,689,000	-2,173,000	-4,131,000	-6,926,000	-5,622,000	-10,156,000	-24,042,000	-23,275,000	-24,980,000	-24,980,000	-32,322,000	-19,820,000	-19,646,000	-6,474,000	-6,474,000	-6,542,000	-3,090,000	-5,035,000	-6,106,000	-6,741,000	-4,881,000	-2,154,000	-3,393,000	-2,263,000	-2,114,000
net cash from investing activities	18,725,000	-291,963,000	-25,058,000	6,256,000	5,962,000	48,224,000	-41,256,000	-55,180,000	-48,437,000	-7,895,000	-11,549,000	3,664,000	13,792,000	15,010,000	27,348,000	2,022,000	-39,506,000	-12,579,000	4,992,000	-112,532,000	-31,418,000	-4,480,000	-4,000	-150,000	19,850,000	-202,000	3,761,000	-1,369,000	-25,033,000	-244,000				0	0	24,000	16,651,000	0	0	0	-1,127,000	-312,000	-1,154,000	-4,534,000	-4,203,000	-14,213,000	-217,000	-8,258,000	-1,409,000	-6,166,000	-230,000	-132,000	-1,459,000	-61,000	-124,000	-84,000	-291,000	-125,000	-594,000	-4,053,000	1,835,000	-8,113,000	445,000	-2,363,000	-1,689,000	-2,173,000	-4,131,000	3,074,000	178,000	35,944,000	-87,693,000	-23,275,000	-24,910,000	-24,910,000	19,553,000	-4,096,000	15,579,000	7,626,000	7,626,000	-116,466,000	13,703,000	27,897,000	26,594,000	16,877,000	-94,466,000	19,890,000	-36,702,000	-1,699,000	-3,269,000
cash flows from financing activities:
principal payments on senior convertible notes	-35,502,000
net proceeds related to issuance of common stock associated with restricted stock units and stock options	105,000
principal payments on financing liability	-279,000	-196,000	-154,000	-176,000	-200,000	-116,000	-79,000
proceeds from market price stock purchase plan	270,000								1,361,000						0	0	684,000					201,000	0							95,000
net cash from financing activities	-35,406,000	247,413,000	71,806,000	-5,510,000	1,390,000	-86,900,000	-2,342,000	-44,550,000	-3,474,000	141,681,000	-283,000	-5,945,000	1,154,000	2,825,000	19,526,000	-1,776,000	813,000	97,370,000	-590,000	-51,490,000	224,977,000	18,694,000	2,640,000	28,188,000	331,000				3,000	35,967,000	-1,823,000	26,622,000	528,000	58,244,000	-22,000	15,416,000	-75,000	117,000	-5,132,000	47,589,000	464,000	49,009,000	-53,213,000	8,686,000	1,186,000	-1,667,000	31,230,000	37,131,000	3,368,000	17,204,000	98,414,000	30,400,000	-349,000	88,234,000	91,259,000	-86,365,000	86,451,000	375,000	34,645,000	18,654,000	9,720,000	15,218,000	103,973,000	38,005,000	39,220,000	15,651,000	68,405,000	45,493,000	59,957,000	30,365,000	-145,000	404,000	-39,000	-39,000	253,857,000	238,000	730,000	389,000	389,000	447,990,000	52,335,000	678,000	581,000	389,000	171,858,000	333,000	100,000	1,558,000	83,169,000
net increase in cash, cash equivalents and restricted cash	-22,046,000	-52,508,000	70,388,000	9,696,000	975,000	-16,032,000	-34,267,000
cash, cash equivalents and restricted cash, beginning of period	75,627,000	0	0	0	47,076,000	0	0
cash, cash equivalents and restricted cash, end of period	53,581,000	-52,508,000	70,388,000	9,696,000	48,051,000	-16,032,000	-34,267,000
impairment loss on available-for-sale investment		0
non-cash lease expense of right-of-use assets
gain on bargain purchase						0
loss on estimated returns of acquired product						0	0	275,000	1,169,000
recognized loss on purchase commitments						-1,000	1,000	-2,021,000	-669,000	-2,614,000	-2,524,000	-2,212,000	-2,074,000	-1,403,000	-1,378,000	-1,426,000	-1,502,000	-920,000	-1,336,000	-1,257,000	-2,379,000	-3,516,000	1,000			0	-411,000	-2,021,000	-1,963,000		-365,000	-5,653,000	-147,000	-4,097,000	-148,000	34,000	-534,000	38,199,000
acquisition of scpharma, net of cash acquired
issuance of note receivable		0
purchase of held-to-maturity securities
proceeds from maturities of held-to-maturity securities
proceeds from insurance claim						0	0	0	396,000	0
proceeds from term loan		250,000,000
payment of loan issuance costs		-4,919,000
payments for taxes related to net issuance of common stock associated with restricted stock units and stock options		1,874,000	-743,000	-5,983,000	1,590,000	91,000	-1,511,000	-4,933,000	266,000	38,000	-1,708,000
proceeds from market price stock purchase plan and employee stock purchase plan		654,000	50,000			819,000	0			745,000	0
milestone right agreement payment		0
principal and early extinguishment payments on midcap credit facility						0	0
proceeds from sale of future royalties
issuance costs associated with sale of future royalties
principal and early extinguishment payments on senior convertible notes
principal and early extinguishment payments on mann group convertible note						0	0
proceeds from at-the-market offering																			0	0	1,886,000				668,000
issuance costs associated with at-the-market offering										0	-67,000	-17,000	-24,000						0	0	-38,000				-20,000
loss on foreign currency transaction			-120,000	5,363,000	2,509,000	-4,433,000	2,454,000	-529,000	-1,399,000			251,000	954,000
amortization of right-of-use assets			740,000	531,000	544,000	528,000	493,000	319,000	328,000	323,000	321,000	319,000	338,000	332,000	324,000	2,042,000	289,000	753,000	-163,000	359,000	309,000	298,000	303,000	294,000	282,000	279,000	285,000	223,000	395,000
interest on mann group convertible note						0	0	1,000	55,000
principal payments on financing lease liability							0
loss on available-for-sale securities						0	0																																															0	0	0	117,000					0	297,000																									-8,000	42,000
milestone payment						0				0				0				0	0																							0	1,000	0	-4,220,000
loss on disposal of fixed assets
net amortization of investments
interest accretion on financing liability
deposits from customer																		-57,000	-310,000
acquisition of v-go														-242,000	0
loss on extinguishment of debt							0											0	-4,930,000											0	712,000	-772,000	825,000	781,000	0							0
purchase of held-to-maturity debt securities							-86,342,000	-119,048,000	-68,399,000	-28,579,000	-24,069,000
proceeds from held-to-maturity debt securities							46,503,000	66,840,000	21,974,000
proceeds from at-the-market-offering										0	4,105,000	1,584,000	1,198,000
principal payment on financing liability									-101,000
principal payment on midcap credit facility									-5,000,000
net increase in cash and cash equivalents									-45,208,000	155,464,000	-3,168,000	315,000	16,102,000		18,801,000																					-4,594,000	25,083,000			36,080,000	-31,421,000	26,146,000	-74,259,000	-13,657,000	3,000	-51,624,000	131,251,000	5,455,000	-35,031,000	-23,013,000	65,274,000	524,000	-33,835,000	60,075,000	-944,000	-53,646,000	53,674,000	-20,105,000	-1,984,000	-22,142,000	-19,149,000	-31,867,000	69,570,000	-694,000	-967,000	-23,899,000	22,590,000	4,214,000	-534,000	-3,934,000	-148,872,000	-88,625,000	-99,206,000	-99,206,000	215,987,000	-64,131,000	-46,324,000	-56,802,000	-56,802,000	276,469,000	16,030,000	-18,833,000	-10,148,000	-13,201,000	49,686,000	-2,537,000	-56,898,000	-17,784,000	66,498,000
cash and cash equivalents, beginning of period									238,480,000	0	0	0	69,767,000		0																				0	0	22,895,000	0	0	0	59,074,000	0	0	0	120,841,000	0	0	0	70,790,000	0	0	0	61,840,000	0	0	0	2,681,000	0	0	0	66,061,000	0	0	0	30,019,000	0	0	0	27,648,000	0	0	0	368,285,000	368,285,000	0	0	0	319,555,000	319,555,000	0	0	0	56,037,000	0	0	0	78,987,000	-7,100,000	0
cash and cash equivalents, end of period									193,272,000	155,464,000	-3,168,000	315,000	85,869,000		18,801,000																				-23,292,000	-4,594,000	47,978,000	-12,635,000	-28,203,000	36,080,000	27,653,000	26,146,000	-74,259,000	-13,657,000	120,844,000	-51,624,000	131,251,000	5,455,000	35,759,000	-23,013,000	65,274,000	524,000	28,005,000	60,075,000	1,734,000	-56,324,000	56,355,000	-20,105,000	-1,984,000	-22,142,000	46,912,000	-31,867,000	69,570,000	-694,000	29,052,000	-23,899,000	22,590,000	4,214,000	27,114,000	-3,934,000	-148,872,000	-88,625,000	269,079,000	269,079,000	215,987,000	-64,131,000	-46,324,000	262,753,000	262,753,000	276,469,000	16,030,000	-18,833,000	45,889,000	-13,201,000	49,686,000	-2,537,000	22,089,000	-24,884,000	66,498,000
net loss										1,401,000	1,721,000	-5,265,000	-9,795,000	-17,947,000	-14,432,000	-29,023,000	-25,998,000	-28,061,000	-4,426,000	-35,523,000	-12,916,000	-26,411,000	-11,255,000	-10,252,000	-9,322,000						-24,164,000	-22,675,000	-30,385,000			-35,339,000	-16,324,000			-29,958,000	-24,873,000	-277,019,000	-31,857,000	-28,911,000	-30,658,000	-36,441,000	-36,519,000	-73,366,000	-52,056,000	-53,583,000	-50,818,000	-46,124,000	-40,965,000	-51,781,000	-42,834,000	-36,578,000	-38,173,000	-36,397,000	-38,402,000	-44,480,000	-41,525,000	-38,306,000	-45,303,000	-42,251,000	-44,700,000	-59,533,000	-45,555,000	-55,604,000	-59,412,000	-83,295,000	-68,497,000	-79,826,000	-71,421,000		-75,013,000	-73,047,000	-71,989,000	-73,141,000		-71,268,000	-60,970,000	-54,751,000	-43,559,000	-33,291,000	-31,730,000	-27,155,000	-22,162,000	-21,150,000	-20,188,000
adjustments to reconcile net loss to net cash from operating activities:
interest on financing liability
asset impairment																		0				0	0
interest on milestone right
accrued interest on mann group convertible note
proceeds from senior convertible notes																																																														-3,000
issuance costs associated with senior convertible notes																		0	0	0	-7,268,000
proceeds from the sale-leaseback transaction
issuance costs associated with the sale-leaseback transaction
deposit for the sale-leaseback transaction
principal payments on mann group convertible note
payment on midcap credit facility										-5,000,000
payment of midcap credit facility prepayment penalty																		0	0
stock-based compensation expense											4,601,000	5,580,000	3,655,000	2,597,000	3,622,000	4,422,000	2,806,000	3,160,000	3,179,000	3,926,000	1,935,000	1,904,000	1,294,000	2,185,000	1,128,000	891,000	1,640,000	2,673,000	999,000	1,142,000	1,563,000	2,209,000	1,943,000	1,084,000	1,247,000	1,249,000	1,267,000	1,005,000	1,502,000	1,355,000	1,273,000	2,347,000	2,600,000	1,775,000	2,003,000	1,867,000	-4,828,000	40,646,000	10,937,000	13,882,000	15,942,000	10,173,000	5,189,000	3,522,000	3,819,000	3,073,000	2,878,000	3,181,000	3,322,000	1,993,000	2,708,000	2,237,000	3,338,000	4,256,000	3,749,000	2,240,000	5,090,000			5,944,000	6,781,000	6,635,000	5,433,000	5,433,000	4,688,000	4,154,000	4,254,000	4,549,000	4,549,000	3,987,000	3,183,000	3,786,000	3,711,000	-1,141,000	2,314,000	-2,216,000	-685,000	-2,571,000	7,004,000
interest expense on mann group convertible note											56,000	54,000	55,000
interest expense on financing liability											-4,847,000	2,449,000	2,424,000	2,425,000	2,313,000	2,443,000	2,371,000
gain on available-for-sale securities											0
gain on foreign currency transaction
proceeds from maturity of debt securities											23,525,000	46,980,000	22,103,000	24,756,000	29,277,000	26,769,000	26,538,000
payment on financing liability											-22,000	-43,000	-72,000	-16,000	1,397,000
net issuance of common stock associated with stock options and restricted stock units													52,000
depreciation, amortization and accretion																		1,220,000	1,324,000	1,016,000	655,000	510,000	534,000	567,000	538,000	565,000	-332,000	372,000	367,000	368,000	1,030,000	753,000	706,000	821,000	920,000	879,000	908,000
interest expense on mann group promissory notes																			82,000	370,000	1,028,000
loss on foreign currency translation																		-1,564,000	-2,068,000			4,008,000	3,927,000							-1,361,000	-728,000	-5,363,000	2,984,000	1,564,000	3,685,000	6,847,000	1,545,000
in-process research and development
accrued interest on mann group promissory notes																		0	0
proceeds from sale of treasury bills																						0	0	0	20,000,000	-2,000
acquisition of in-process research and development, net of cash acquired
issuance costs associated with at the market offering																						-150,000	-37,000
proceeds from market price stock purchase plan and from employee stock purchase plan
issuance of common stock from the exercise of warrants																						0	0
proceeds from midcap credit facility																										0
proceeds from ppp loan
proceeds from the senior convertible notes																		0	0	0	230,000,000
principal payments on mann group promissory notes																		0	0
payment of midcap credit facility																		0	0
net increase in cash and cash equivalents and restricted cash																	-56,941,000	72,444,000	-10,782,000	-185,469,000	180,828,000	14,449,000	-10,824,000	24,354,000	8,962,000							-528,000	-21,122,000
cash and cash equivalents and restricted cash, beginning of period																	124,184,000	0	0	0	67,163,000	0	0	0	30,222,000	0	0	0	71,684,000	0	0	0	48,355,000
cash and cash equivalents and restricted cash, end of period																	67,243,000	72,444,000	-10,782,000	-185,469,000	247,991,000	14,449,000	-10,824,000	24,354,000	39,184,000	-267,000	17,205,000	-21,773,000	35,057,000	60,711,000	-15,732,000	-528,000	27,233,000
interest on milestone payment																			0
interest expense on mann group promissory note
gain on foreign currency translation															-1,799,000	-4,503,000	-1,983,000				-3,838,000				-1,796,000	2,582,000
payment-in-kind interest on mann group promissory note
accrued interest on mann group mann group promissory note
customer deposits															-1,563,000	-5,491,000	2,104,000
purchase of debt securities															-1,658,000	-12,482,000	-55,988,000		-96,486,000	-108,478,000	-30,442,000
payment of employment taxes related to vested restricted stock units and exercise of stock options															-192,000	-377,000	129,000	240,000	-590,000	-545,000	397,000	332,000	102,000
principal payments on mann group mann group promissory note
supplemental cash flows disclosures:
interest paid in cash															802,000	741,000	3,600,000																																											4,632,000	5,504,000	5,008,000	2,523,000	4,258,000	1,873,000	3,972,000	1,398,000	2,749,000	12,000						2,156,000	0
non-cash investing and financing activities:
reclassification of investments from long-term to current															19,854,000	37,423,000	14,813,000
payments on debt and interest through common stock issuance															99,000
modification of operating leases															0
addition of right-of-use asset															0
non-cash construction in progress and property and equipment															517,000	533,000	383,000		-1,029,000	1,059,000	124,000				32,000																558,000		-431,000	-471,000	1,094,000	-2,041,000	844,000	1,265,000	1,700,000	-4,667,000	918,000	742,000	3,863,000	1,165,000	564,000	1,422,000	921,000	69,000	-858,000	-3,332,000	4,371,000	279,000	1,004,000			-619,000	-1,575,000	-4,467,000	7,281,000						-1,636,000
common stock issuance to settle employee stock purchase plan liability															873,000	0	740,000				390,000	0	366,000	0	318,000	0	339,000	0	317,000
contingent milestone liability															0
premium on mann group convertible note																			0
forgiveness of ppp loan
interest expense on promissory notes																86,000	116,000					1,296,000	1,316,000	1,279,000	1,257,000	1,195,000
ut owned property and equipment
payment on mann group convertible note through issuance of common stock																			2,000	0	9,573,000
payment of 2024 convertible notes through common stock issuance																					5,000,000
reclassification of the ppp loan from current to long-term																					609,000
payment of mann group convertible note interest through issuance of common stock																			0	0	427,000
payment of interest on 2024 convertible notes through common stock issuance																					143,000
amortization of financing liability
proceeds from sale of debt securities
proceeds from market price stock purchase																			0
interest paid in cash, net of amounts capitalized																			3,818,000	5,623,000	1,094,000	697,000	1,041,000	935,000	885,000					864,000	1,035,000	0	1,860,000	1,355,000	2,232,000	1,591,000	2,550,000		2,590,000	1,895,000	2,713,000		4,795,000	1,895,000	4,749,000		4,444,000	618,000	4,678,000		2,856,000	2,143,000	2,863,000		2,875,000	2,156,000	2,595,000	2,156,000
right-of-use asset modification
addition of operating lease liability
operating lease liability modification
payment of 2024 convertible notes through issuance of common stock																			0
issuance of common stock under employee stock purchase plan																			700,000
payment of interest on 2024 convertible notes through issuance of common stock																			0
payment of principal on senior convertible notes through issuance of common stock
receivable from at-the-market offering
payment-in-kind interest on promissory notes																										0
loss on warrant transactions
purchase of treasury bills																										-91,000
purchase of limited liability company ownership interest																										0
proceeds from at the market offering																						8,311,000	2,575,000
proceeds from paycheck protection program loan																						0	0
proceeds from promissory notes																										0
principal payments on promissory notes
principal payments on facility financing obligation																										0	-4,420,000			-3,000,000				0	0
issuance cost associated with midcap credit facility																										0
repurchase of warrants
issuance cost associated with promissory notes
issuance of common stock for acquisition of in-process research and development
payment on promissory notes through issuance of common stock
payment on interest of promissory notes through issuance of common stock
payment of senior convertible notes through common stock issuance																										0
payment of interest on senior convertible notes through common stock issuance																						0	144,000	0	144,000	0	537,000	4,000	534,000
issuance of warrants associated with midcap credit facility
receivable from at the market offering																						-348,000	104,000
addition of right-of-use assets upon adoption of new lease guidance																										0	0
payment of facility obligation through common stock issuance																										0
gain on extinguishment of debt
accrued interest on promissory notes
payment of principal on senior convertible notes through common stock issuance																							0
impairment of commitment asset																									1,521,000
exercise of stock options																									8,000	74,000	32,000
payment of employment taxes related to vested restricted stock units																									-325,000						0	-103,000	-81,000	-17,000	-22,000	-13,000	-75,000	-4,000	-158,000	0	-3,000	-25,000	-1,015,000	-56,000	-762,000	-64,000	-26,721,000	-90,000	-33,000	-2,706,000	-1,647,000	-21,000	-427,000	-19,000	-482,000	-8,000	-397,000	-22,000	-475,000	-24,000	-26,000	-55,000	-2,035,000	-49,000	-1,253,000	-208,000	-6,575,000	-175,000	-43,000	-112,000	-146,000	-20,000	-39,000	-39,000	-324,000	-141,000	-19,000	-40,000	-40,000
gain on sale, abandonment/disposal or impairment of property and equipment
proceeds from sale of property and equipment																														110,000				0	0			0	0	0	17,000	4,000												4,000	0	41,000	32,000	30,000	0											0	0	0	70,000	70,000						0	0			0	0	-6,000	96,000
issuance cost associated with mann group promissory notes
proceeds from public offering
proceeds from direct placement																																							0
issuance cost associated with public offering
issuance cost associated with direct placement																														0	0
income taxes paid in cash
(gain) loss on extinguishment of debt
right-of-use and other assets																											0	-16,000	-340,000
accrued interest - promissory notes
proceeds of senior convertible notes
payment of senior convertible notes
proceeds from direct placement of common stock																														0	0
proceeds from executive stock purchase plan
proceeds from issuance of common stock pursuant to at-the-market offering
issuance cost associated with in at-the-market offering
net cash (used) provided by financing activities																											65,495,000
net decrease in cash and cash equivalents and restricted cash																											17,205,000	-21,773,000	-36,627,000
property and equipment in progress in accounts payable																											-587,000	544,000	246,000
principal and interest payments on promissory notes through common stock issuance
payment of note obligations through common stock issuance																																	9,407,000
accrued but unpaid debt issuance costs																															-10,000
(gain) loss on foreign currency translation																												1,247,000	-1,935,000
interest on note payable to related party																												1,163,000	1,134,000	1,143,000	1,126,000	1,097,000	1,122,000
operating lease payments																												-304,000	-395,000
purchase of short-term investments																												-145,000	-24,764,000
proceeds from issuance of common stock pursuant to at-the-market issuance																														1,270,000	185,000	0	634,000
issuance cost of at-the-market transactions																															-8,000	0	-25,000
payment of note payable to related party through common stock issuance																															0	0	8,160,000
restricted stock unit award																													105,000
accrued but unpaid debt issuance costs related to note payable to related party																																	75,000
addition of right-of-use assets																													5,192,000
change in fair value of warrant liability																																		0	1,288,000	-147,000	-6,629,000
interest incurred through borrowings under sanofi loan facility																																						353,000	1,521,000	1,436,000	1,168,000
series a warrant issuance cost
loss on sale, abandonment/disposal or impairment of property and equipment																														-104,000																				131,000	0			755,000	0	-41,000	-32,000	59,000	0							12,807,000
gain on purchase commitments
receivable from sanofi																																		0	0	0	30,557,000
deferred costs from commercial product sales																																		138,000	-43,000	-28,000	-163,000	-30,000
deferred costs from collaboration																																						0
deferred payments from collaboration																																2,112,000	-63,000	-63,000	-62,000	-62,000	-63,000
deferred sales from collaboration																																						0	-26,882,000
loss on purchase commitments
net proceeds from sale of asset held for sale																																		0	0
proceeds from public offering — common stock
proceeds from issuance of common stock																																						121,000	38,000	267,000	467,000
borrowings on note payable to related party
issuance costs of at-the-market transactions
payment of note obligations and interest through issuance of common stock
payment of note payable to related party through issuance of common stock
capitalization of interest on note payable to related party																																																						2,343,000	0
reclassification of deferred payments from collaboration to sanofi loan facility and loss share obligation																																						461,000	-290,000
reclassification of property and equipment to asset held for sale
reclassification of warrant liability to additional paid-in capital																																		-13,000
deferred payments from collaborations
payment of note obligations through common stock issuance, net of issuance costs
interest on note payable to principal stockholder																																		1,174,000	1,173,000	721,000	714,000
receivable from collaboration
milestone rights liability and other liabilities
proceeds from issuance of common stock under tel aviv stock exchange
issuance cost associated with the tel aviv stock exchange
exercise of warrants for common stock																																																	1,938,000	44,977,000	20,862,000
payment of debt issuance costs on senior convertible notes
borrowings on note payable to principal stockholder																																		0	0
capitalization of interest on note payable to principal stockholder																																		0	0
gain on disposal of property and equipment																																			0
warrant issuance cost
net decrease in cash and cash equivalents
repayment of facility financing obligation through issuance of common stock																																			0
deferred revenue—net
reclassification of deferred costs from loss on purchase commitment to deferred costs from collaboration
deferred revenue - net																																					-1,575,000
net proceeds from sale of property and equipment																																					16,651,000
cost incurred for construction in progress included in accounts payable and accrued liabilities
series a warrant issuance costs
write-off of tranche b commitment asset
write-off of derivative liability																																														0	0
receivables from collaboration																																								144,000	-121,000	1,656,000	3,069,000	-466,000	46,154,000
proceeds from direct placement of common stock and warrants
issuance costs associated with direct placement																																						0
payment of notes payable to deerfield
issuance costs associated with the tel aviv stock exchange
payment of 2015 notes																																										0
payment of debt issuance costs on 2018 notes																																										0
proceeds from issuance of facility financing obligation and milestone rights
proceeds from issuance of tranche b of the facility financing obligation																																														0	0
interest paid in cash, net of amounts capitalized to construction in progress
payment of 2015 notes and interest through issuance of common stock																																										0
issuance of common stock pursuant to debt conversion by deerfield
depreciation and accretion																																							1,039,000	1,035,000	1,023,000	3,182,000	3,470,000	3,636,000	2,988,000	3,001,000	2,960,000	3,220,000	9,394,000	3,948,000	3,441,000	3,320,000	3,348,000
loss on disposal of property and equipment																																											15,000
interest on note payable to our principal stockholder
loss on foreign currency exchange																																							1,012,000	-341,000	2,364,000
warrant fair value adjustment																																							-13,185,000
series a warrant issuance costs included in financing
deferred payment from collaboration
principal payments on notes payable to deerfield
issuance costs of at-the-market issuance
adjustments to reconcile net loss to net cash from (used) in operating activities:
changes in assets and liabilities:
purchase commitment loss - current
non-current purchase commitment loss
other liabilities																																									721,000	734,000	728,000	722,000	743,000	729,000	751,000	721,000	714,000																					0	0	0	-24,000	-24,000						0	0	0	-5,000	-7,000	-7,000	-5,000	-28,000	16,000	-78,000
issuance costs associated with the direct placement
proceeds from issuance of common stock pursuant to atm issuance																																											12,486,000
deferred product costs from collaboration																																										0	-2,708,000	-4,580,000	-6,251,000
deferred product sales from collaboration																																									177,000	29,000	4,070,000	5,918,000	7,050,000
write-off tranche b commitment asset
foreign exchange loss
payment of 3.75% senior convertible notes due 2013
proceeds from issuance of facility financing obligation & milestone rights																																														0				40,000,000
facility financing obligation & milestone rights issuance costs																																																		0
reduction of principal on note payable to principal stockholder upon issuance of common stock and exercise of warrants
interest paid through borrowings under sanofi loan facility
write off of derivative liability
income from sale of intellectual property
interest expense related to milestone payment
deferred up-front payment from collaboration agreement
proceeds from sale of intellectual property
proceeds from issuance of common stock and warrants
issuance costs of atm
issuance of common stock pursuant to conversion of facility financing obligation																																															0	7,500,000	86,000,000
reclassification of share-based awards to liability																																															42,889,000
tranche b commitment asset																																															0	-1,168,000	2,921,000
reclassification of deferred payments from collaboration to sanofi loan facility
issuance of common stock and warrants, net of issuance costs																																												6,652,000	6,168,000	1,547,000	17,951,000	19,159,000	1,463,000	49,933,000	297,000	2,113,000	78,000		0	-80,518,000	80,598,000
issuance of common stock for notes receivable
adjustments to reconcile net loss to net cash provide by (used in) operating activities:
fair value of forward purchase contract																																																						13,248,000	0	-10,306,000	-1,705,000
common shares issued pursuant to litigation settlement
commitment to deliver common shares pursuant to litigation settlement
state research and development credit exchange receivable																																														752,000	-600,000	-83,000	-82,000	224,000	399,000	-79,000	-78,000	-20,000	-85,000	-93,000	-92,000	678,000	-266,000	518,000	-100,000	-147,000	196,000	-199,000	1,265,000	-218,000	-350,000	-175,000	1,325,000	-375,000	-375,000	-375,000	456,000	456,000	1,965,000	372,000	-375,000	-375,000	-375,000	-375,000	-250,000	-374,000	306,000				-366,000
deferred cash payments from collaboration
payment of 2013 notes
payment of milestone rights
borrowings on notes payable to principal stockholder
forward purchase contracts contribution to additional paid-in capital
reclassification of forward purchase contracts to additional paid-in capital
reclassification of collaboration loan facility obligation
stock expense for shares issued pursuant to research agreement
accrued interest on investments, net of amortization of discounts																																																																			0	0	-12,000
goodwill impairment
litigation settlement in stock
purchase of marketable securities																																																																		0	0	0	-2,000,000	0					-129,950,000	-36,401,000	0	-3,450,000	-3,450,000	-116,924,000	-13,557,000	-7,700,000	-16,250,000	-41,950,000	-146,650,000	-2,650,000	-66,900,000	-11,354,000	-2,385,000
sales and maturities of marketable securities																																																										0	0
collection of series c convertible preferred stock subscriptions receivable																																																																																								0	0
issuance of series b convertible preferred stock for cash
cash received for common stock to be issued
repurchase of common stock
put shares sold to majority stockholder
borrowings under lines of credit
proceeds from notes receivables
principal payments on notes payable to principal stockholder
borrowings on notes payable
principal payments on notes payable
cash paid for income taxes																																																																																		4,000	1,000	0	0	0	1,000
accretion on redeemable convertible preferred stock																																																																																								0	0
issuance of common stock upon conversion of notes payable
increase in additional paid-in capital resulting from merger
issuance of put option by stockholder
put option redemption by stockholder
issuance of series c convertible preferred stock subscriptions
issuance of series a redeemable convertible preferred stock
conversion of series a redeemable convertible preferred stock																																																																																								-60,000
forward purchase contract contribution to apic
reclassification of forward purchase contract to apic
accrued interest on investments, net of amortization of premiums																																																																																7,000	0	0	197,000	-39,000	-132,000
principal payments on notes payable to our principal stockholder
borrowings on notes payable to related party																																																							5,000,000	0	6,250,000		35,000,000				10,000,000	37,000,000	40,000,000		15,000,000
principal payments on notes payable to related party
cancellation of principal on note payable to related party																																																										0	0	0	11,116,000
issuance of common stock and warrants for cash																																																																																	2,335,000	678,000	581,000	389,000
borrowings on notes payable from related party
reduction of principal on note payable to related party upon issuance of common stock and warrants
reduction of principal on note payable to related party upon issuance of common stock
forward purchase contract contribution to additional paid-in capital																																																							0
reclassification of forward purchase contract to additional paid-in capital																																																							0
fair value adjustment of warrant liability																																																								-2,993,000	284,000
warrant liability																																																								1,000	7,631,000
issuance of common stock and warrants																																																										397,000	120,000	678,000	9,746,000	15,276,000	222,000	1,054,000	473,000	859,000	59,980,000			477,000	1,000				254,181,000	379,000	749,000	429,000	429,000
sales/ maturities of marketable securities																																																													3,828,000						0
(gain) loss on sale, abandonment/disposal or impairment of property and equipment
deposit for purchase related to pfizer agreement																																																																					-10,000,000
sales of marketable securities																																																																					17,800,000						181,825,000	52,125,000	35,225,000	17,550,000	17,550,000	7,000,000	30,350,000	40,600,000	48,950,000	65,550,000	56,500,000	24,700,000	33,495,000	11,918,000	1,230,000
borrowings on notes payable from principal stockholder																																																																					60,000,000
payable to stockholder																																																																																								0	0
non-cash transfer from property and equipment to other current assets
stock—based compensation expense																																																																					5,836,000
in—process research and development
discount on stockholder notes below market rate
non—cash compensation expense of officer resulting from stockholder contribution
accrued interest expense on notes payable to stockholders
non—cash interest expense
accrued interest on notes receivable
loss on available—for—sale securities
increase in additional paid—in capital resulting from merger
non-cash compensation expense of officer resulting from stockholder contribution
non-cash interest expense
loss on sale and abandonment/disposal of property and equipment																																																																							0	127,000	-6,000	-6,000						28,000	65,000			17,000	23,000	-22,000	-2,000	163,000	323,000
proceeds from notes receivable
cash paid during the period for income taxes
cash paid during the period for interest
supplemental schedule of non-cash investing and financing activities:
construction in progress purchases in accounts payable and accrued expenses
transfer from fixed assets to other current assets
noncash construction in progress																																																																								1,506,000	13,269,000	13,269,000			1,941,000	5,851,000	5,851,000
noncash transfer from fixed assets to other current assets
payment of deferred compensation																																																																																				0	0			0	0
restricted cash																																																																																				18,000	0	567,000	-2,000	-2,000	-2,000
notes receivable by stockholder issued to officers
accrued interest on notes																																																																																								-29,000	-27,000
borrowing on notes payable
note payable to principal stockholder
(gain)/loss on sale and abandonment/disposal of property and equipment
state r&d credit exchange receivable																																																																																					-1,132,000
issuance of common stock for cash																																																																																						333,000	100,000	1,558,000	83,169,000
non-cash compensation to officers
notes receivable by stockholder to officers																																																																																									0
stock issued for services
conversion of series b convertible preferred stock
conversion of series c convertible preferred stock

MannKind Corporation(NASDAQ:MNKD)

MannKind Corporation
(NASDAQ:MNKD)